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Porcine circovirus type 2 (PCV-2) is considered the major cause of porcine circovirus-
associated diseases and is one of the major pathogens in swine producing countries. 
PCV-2 is a non-enveloped virus with a single stranded circular DNA genome of about 
1.8 kb. This encodes the single capsid protein (CP) which is highly immunogenic, as 
well as a replication-associated protein. Recombinantly expressed CP can self-
assemble into virus-like particles (VLPs) that are structurally and immunogenically 
very similar to native virions. Current commercially available diagnostic kits are VLP-
based and are effective at detecting PCV-2 antibodies in sera. However, these 
diagnostic assays are expensive, therefore limiting their use in developing countries. 
Plant-based transient expression systems have recently been investigated to express 
PCV-2 CP for a cheaper diagnostic reagent.  
The aim of this study was to develop an inexpensive lateral flow device to be able to 
test for PCV infection in pig herds. Production of PCV-2 CP in Nicotiana benthamiana 
via transient Agrobacterium-mediated expression was optimised by comparing two 
expression vectors, pEAQ-HT and pCBP2, and VLPs were also expressed in 
Escherichia coli. VLPs produced in plants and in E. coli were used to set up a lateral 
flow device. In addition, various purification methods of VLPs such as ion exchange 
chromatography (IEC) and sucrose gradient ultracentrifugation were explored to 
obtain pure VLPs free of bacterial contamination.  
The VLPs were successfully expressed in N. benthamiana with both pEAQ-HT and 
pCBP2, and VLPs were subsequently purified on discontinuous sucrose gradients by 
ultracentrifugation. The assembly of the CP was assessed by transmission electron 
microscopy, which showed the presence of assembled VLPs.  To further purify the 
VLPs IEC was used, and fully assembled VLPs which were free of contamination were 
prepared. Purified VLPs expressed in plants and E. coli were successfully used as 
coating antigen in lateral flow devices, which were able to detect PCV-2 CP antibodies 
in CP-immunised rabbit sera. E. coli-made VLPs showed higher affinity to PCV-2 
antibodies compared to plant-made VLPs. 
In conclusion, this study has successfully demonstrated the potential to use a plant-
based transient expression system to produce affordable diagnostic reagent, 
especially for developing countries. This is the first study that expressed PCV-2 VLPs 
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using a pCBP-2 expression vector and used PCV-2 VLPs as a coating reagent in the 

































APE  acute pulmonary edema 
BCIP  5-bromo-4-chloro-3-indoxyl-phosphate 
BSA  bovine serum albumin  
BSL  biosafety level 
CP  capsid protein 
ELISA  enzyme-linked immunosorbent assay 
ER  endoplasmic reticulum 
FDA  food and drug administration 
GAG  glycosaminoglycans 
GCD  glucocerebrosidase 
IEC  ion exchange chromatography 
IFA  indirect fluorescent antibody 
IHC  immunohistochemistry 
IIFA  indirect immunofluorescence assays 
IPM  immune peroxidase monolayer 
IPTG  isopropyl β-D-thiogalactopyranoside 
LB  Luria Bertani 
LPH              leader peptide (derived from murine heavy chain of mAb24) 
LSD  lysosomal storage disorder 
MES  morpholineethanesulforic acid 
NBT  nitroblue tetrazolium 
NGC  non-gas chromatography 
NK  natural killer 
NLS  nuclear localization signal 
OD  optical density 
ORF  open reading frame 
PBS  phosphate buffer saline 
PCR  polymerase chain reaction 
PCV  Porcine circovirus 
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PCVAD  porcine circovirus associated diseases 
PDNS  porcine dermatitis and nephropathy syndrome 
PMWS postweaning multisystemic wasting syndrome 
PRDC  porcine respiratory disease complex 
PRRSV porcine reproductive and respiratory syndrome virus 
PTGS  post-transcriptional gene silencing 
PVX  potato x virus 
RCR  rolling-circle replication 
RFLP  restriction fragment length polymorphism 
RNA  ribonucleic acid 
SAB  sample application buffer 
TBSV  tomato bushy stunt virus 
TEM  transmission electron microscopy 
TMV  tobacco mosaic virus 
TSWV  tomato spotted wilt virus 
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1 Chapter 1: Literature review 
 
1.1 Background 
Porcine circovirus (PCV) is one of the smallest DNA viruses that infect mammals and 
is a global threat to swine (Kennedy et al., 2000, Bolin et al., 2001). There are currently 
four different categories of PCV in swine populations. In 1974, PCV type 1 (PCV-1) 
was discovered, however it has not been associated with any known animal disease 
although it is widespread in swine (Allan et al., 1995). Since then, PCV-2 was identified 
retrospectively in swine herds in northern Germany from 1997 (Jacobsen et al., 2009, 
Bolin et al., 2001, Zhai et al., 2014b) and in South Africa, the virus was first identified 
in June 2001 at a large, well-managed commercial breeding facility in Gauteng 
Province (Drew et al., 2004). Furthermore, in 2015 PCV-3 was identified as a new 
subtype of PCV on a farm in North Carolina, United States of America (USA) (Palinski 
et al., 2017a). Interestingly, in 2016 the same strain of PCV was discovered in 
Guangxi, China (Wen et al., 2018). Recently, a novel PCV strain was discovered within 
the swine population of Hunan Province in China and it was referred to as PCV-4 
(Zhang et al., 2020a). 
In Germany, PCV was initially discovered in a pig kidney cell line (PK-15) as a 
picornavirus-like contaminant with no cytopathic effect. It was first thought that PCV 
has a ribonucleic acid (RNA) genome (Tischer et al., 1974). However, it was later 
discovered that PCV is a single stranded deoxyribonucleic acid (ssDNA) virus. 
Experiments revealed that  PCV isolated from the PK-15 cells was PCV-1 and that it 
did not cause any sickness in pigs (Tischer et al., 1982).  Subsequently in 1991, an 
emergence of PCV-2 occurred in Saskatchewan, Canada, from infected pigs which 
had symptoms of weight loss, jaundice, discomfort in breathing and microscopic 
lesions in lymphoid tissues. Furthermore, PCV was also discovered on nearly all 
continents around the world (Allan et al., 1998, Harding, 1998). The non-pathogenic 
strain of PCV was designated PCV-1 and the pathogenic was termed PCV-2 (Allan et 
al., 1999b).  
From 1961 to 1984, the total number of global incidences of PCV-2 was minimal  
compared to the number of incidences that occurred between the period of 1985 to 
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1998 (Jacobsen et al., 2009). So far the epidemiological data shows that PCV-2 has 
possibly been in existence for over five decades in the swine population worldwide 
(Jacobsen et al., 2009, Rose et al., 2012, Afolabi et al., 2017b).  
PCV-2 is regarded as one of the major threatening pathogens affecting all swine 
producing countries, causing severe economic losses to the pig industry. Wild boars 
can also be affected by this virus. However, they rarely show clinical symptoms, 
although PCV-2 serological prevalence is as high as in domestic swine (Beach and 
Meng, 2012). In the early 1990s, PCV-2  was first discovered to be the causative agent 
associated with porcine circovirus associated diseases (PCVAD) (Chae, 2005). PCV-
2 associated diseases were primarily seen in samples archived in 1985 (Jacobsen et 
al., 2009).  In recent years, PCV-2 has received much attention due to its negative 
impact on the profitability of pork production (Chen et al., 2018). This literature will 
review PCV-2 as the major causative agent of PCVAD, the vaccines that are used to 
reduce PCV-2 infections, diagnosis of these diseases and challenges associated with 
these. 
 
1.2 Classification  
PCV-2 belongs to the genus Circovirus, within the family Circoviridae.  Phylogenetic 
analysis of PCV-2 viruses from both symptomatic and asymptomatic infected pigs 
around the world, has shown that there are five major genotypes. These are grouped 
by their capsid protein coding sequence: PCV-2a, PCV-2b, PCV-2c, PCV-2d and 
PCV-2e (Meehan et al., 1998, Olvera et al., 2007). However, a recent study conducted 
in China identified new viral sequences that cluster differently from the existing 
sequences and classified these as genotype PCV-2f and PCV-2g (Figure 1.1) (Franzo 
and Segales, 2018).  These genotypes have a nucleotide sequence identity of more 
than 94%, with  90-100% amino acid sequence identity (Melanie et al., 2019, Meehan 




Figure 1.1 Phylogenetic tree of PCV-2 genotypes. Tree obtained with permission from Franzo and Segales (2018).
4 
 
From 1996 to the early 2000’s PCV-2a was the predominant genotype in global swine 
herds. Since then, this has changed due to a genotype shift, with the emergence of 
PCV-2b from Europe and North America which has been shown to be the most widely 
spread PCV pathogen worldwide (Figure 1.2), with an observed increase in associated 
disease outbreaks.  A third genotype,  PCV-2c, was reported in the 1980’s from 
Denmark (Dupont et al., 2008). PCV-2d first appeared in China, then a second 
genotype shift (from PCV-2b to PCV-2d) occurred in 1999 in which PCV-2d became 
the main PCV-2 pathogen. This is  suggested to have been  driven by the worldwide 
use of PCV-2 vaccines (Mo et al., 2019, Beach and Meng, 2012, Franzo and Segalés, 
2018, Dupont et al., 2008). According to Xiao et al. (2015). The PCV-2d genotype now 
consists of PCV-2 strains previously classified as PCV-2b subtype 1C and those 
classified as mutant PCV-2b (mPCV-2b), arising from PCVAD clinically manifested 
pigs in suspected vaccine failure (Guo et al., 2012, Opriessnig et al., 2013). The third 
genotype, PCV-2c has not been of serious economic importance since it was only 
initially found in Danish archived samples from healthy herds and then in wild pig 
samples in Brazil (Dupont et al., 2008).  
 
 
Figure 1.2 Geographic distribution of main PCV-2 groups. The PCV-2 cluster 
distribution was summarized using pie-charts that are specific to continents whose 





It has been shown that PCV-2d shows virulence similar to that of PCV-2a and PCV-
2b when inoculated into susceptible pigs. The clinical significance of PCV-2c, PCV-2e 
and PCV-2f are not known. New genotypes are likely to appear in the future since 
PCV-2 is a single stranded DNA virus with a high nucleotide substitution rate 
(comparable to those of RNA viruses) and there is high potential for genome mutations 
(Franzo and Segalés, 2018). 
 
1.3 PCV genome 
PCV has a circular, ssDNA genome of approximately 1.8 kb in size.  The virion is non-
enveloped with a diameter of 12 to 23 nm (Rodriguez-Cariñg and Segales, 2009, 
Fauquet et al., 2005, Todd, 2005, Mankertz et al., 2000). PCV is the smallest known 
animal DNA virus with a highly conserved genome in terms of the amino acid 
sequence. However, for a typical ssDNA virus, the rate of nucleotide substitution in 
the viral genome per site and year is considered to be the highest of its kind (Xiao et 
al., 2015). 
The ssDNA genome of PCV-2 encodes four major open reading flames (ORFs, Figure 
1.3) (Mankertz et al., 2000, Meehan et al., 1998), oriented in opposite directions (Chen 
et al., 2018, Nawagitgul et al., 2000). ORF1 encodes two DNA replication-associated 
proteins (Rep and Repʹ) whereby Rep is very conserved, whereas Rep’ is a truncated 
form and a result of alternative splicing of a C-terminal of ORF1 (Chen et al., 2018, 
Mankertz et al., 2004).ORF2 encodes the capsid protein (CP), a structural protein of 
PCV-2 associated with its pathogenicity (Hu et al., 2016, Nawagitgul et al., 2000). In 
addition, ORF2 has been shown to be a good phylogenetic and epidemiological 
marker for PCV-2 since it gene sequences reconstruct the same phylogenetic tree 
when compared to using the whole PCV-2 genome (Grau-Roma et al., 2008). This 
gene is transcribed from the complementary strand in the replicative form of the virus 
to produce a 233 amino acid CP that is approximately 27kDa (Karuppannan and 
Opriessnig, 2017a). PCV-2 CP is capable of self-assembly into virus-like particles 
(VLPs) that are similar to the icosahedral morphology of the native PCV-2 virions when 
recombinantly expressed (Yin et al., 2010).  
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ORF3 is located within ORF1 and is not crucial in viral replication but is involved in 
inducing cell apoptosis/pro-apoptosis (Ren et al., 2016). This is  essential in the 
development of viral pathogenesis (Júnior et al., 2012).  ORF4 has been identified and 
is embedded within ORF3 and oriented in the same direction. Similarly to ORF3, ORF4 
is not crucial in virus replication (Lv et al., 2014, He et al., 2013). It encodes a protein 
of approximately 60 amino acids with anti-apoptotic function and plays a major role in 
limiting ORF3 transcription thus inhibiting virus-induced apoptosis (Klaumann et al., 
2018, Gao et al., 2014). The genome of PCV-2 has a stem loop structure at the origin 
of replication (ori) that is well maintained between two small intergenic regions (IR), 
this structure also exists in diverse ssDNA viral families that infect eukaryotes such as 
Nanoviridae and geminiviruses (Karuppannan and Opriessnig, 2017a).  The 
replication associated proteins recognizes distinctive structures of stem loop in the 
genome of the virus and, in conjunction with the machinery of host cells that is likely 
to have been involved in previous DNA repair synthesis resulting in double stranded 
DNAs (dsDNA) form of the genome. After nicking of the DNA strand, the Rep binds to 
the new 5 ends covalently and initiates rolling circle replication (Finsterbusch and 
Mankertz, 2009). 
 
Figure 1.3 Genomic representation of PCV-2. Four ORFs are shown, with the stem 
loop (SL) structure located in the IR between ORF1 and ORF2. The Rep is translated 
from the full-length ORF1, whereas the Rep′, Rep3a, b & c are produced via alternative 






According to Khayat et al. (2011), the crystal structure of the in vitro assembled PCV-
2 VLPs shows that these consist of 60 copies of PCV-2 CP with icosahedral symmetry 
and several exposed loops on the viral surface. These serve as immunodominant 
epitopes that trigger neutralising antibodies (Khayat et al., 2011, Liu et al., 2016).  The 
crystal structure of the N-terminally truncated PCV-2 CP has a resolution of 2.3 Å, 
whereas the in vitro assembled full-length PCV-2 VLP has a 9.6 Å resolution.  
A comparison of the PCV-2 capsid crystal structure and  cryo-EM images of the PCV-
2 capsid shows that the Cap Nuclear Localization Signal (NLS) is located at the 5-fold 
icosahedral axis (Figure 1.4) (Khayat et al., 2011, Mo et al., 2019). The NLS consist 
of positively charged arginine (R) residues (Figure 1.4C). The arginine-rich residues 
which are next to the NLS-A reach onto the adjacent capsid protein and then interact 
with its NLS-B fragment to stabilize VLP formation (Figure 1.4 C-D). In addition, the 
rate and or stability of VLP formation is greatly determined by the amino acid type and 
charge. A polyarginine peptide is generally recognized as a cell penetrating peptide 
(CPP), which can disrupt cell membranes and carry foreign proteins and chemicals 
(and even beads) into cells (van den Berg and Dowdy, 2011) 
 
Figure 1.4 Cryo-EM of full-length PCV-2 VLP structure A: A 3D reassembled cryo-EM 
form of PCV-2 VLP showing a typical T=1 icosahedral particle fold. B: Internal 
structural feature of the NLS fragment with one-half of the density map was removed. 
C: Density map of NLS region. The density maps are shown for NLS-A, NLS-B, α-
helices etc. D: The interaction of cation-π between 37Arg and 28Trp residues. Image 




1.5 PCV-2 and its associated diseases 
1.5.1 Postweaning multisystemic wasting syndrome and PCVAD 
PCV-2 causes postweaning multisystemic wasting syndrome (PMWS) and is strongly 
associated with other diseases in pigs, such as porcine dermatitis and nephropathy 
syndrome (PDNS) , porcine respiratory disease complex (PRDC), acute pulmonary 
edema (APE), proliferative and necrotizing pneumonia, myocarditis in stillborn piglets 
and occasionally failure in reproduction (Allan et al., 1999a, Bolin et al., 2001, Harding 
and Clark, 1997, Bogdan et al., 2001). PMWS has become established in many 
countries worldwide as a major disease in pigs (Krakowka et al., 2000).  
According to Young et al. (2011) & Segalés et al. (2005), diseases linked to PCV-2 
are collectively named porcine circovirus diseases (PCVD) or PCVAD in North 
America. It was clear that almost every pig that has the virus, became infected 
sometime during its growing period. Although pigs were infected with PCV-2, some of 
them had no clinical manifestation of PCVAD. 
 
1.5.2             PCV-2:  First occurrence in South Africa pig herds 
In 2001, a PCV-2 outbreak was recorded in the Gauteng province of South Africa 
(Drew et al., 2004). Here, 1-2-month-old pigs clinically presented PDNS. These 
symptoms were immediately followed by PMWS clinical signs and five months later, 
morbidity increased to 30-40% while the mortality rate was below 10% (Drew et al., 
2004). Another study in South Africa by Afolabi et al. (2017a), reported that swine 
herds of the Eastern Cape District were observed to have typical clinical symptoms of 
PMWS (Figure 1.5). PCV-2 was also detected and characterized in other Sub-Saharan 
African countries such as Uganda as indicated below. 
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Figure 1.5: Wasting appearance of a pig with severe respiratory difficulty within a herd 
of the same age at a farm in Lukhanji Local Municipality, Chris-Hani District, Eastern 
Cape, South Africa  (Afolabi et al., 2017b).  
1.5.3        PCV-2 among Ugandan domestic swine 
A study conducted by Jonsson (2013) in Uganda, focused on assessing PCV-2 in 
domestic pigs. Here, sampling and analysis of 91 pigs around Murchison Falls national 
park was performed. Approximately 77% of the sampled pigs tested positive for PCV-
2 and were associated with PMWS. This is in agreement  with the results obtained by 
Ojok et al. (2013). The sampling size was small to achieve a more reliable conclusion, 
therefore, Jonsson (2013) recommended that more studies need to be carried out in 
order to obtain reliable results . 
 
1.6 Aetiology 
1.6.1 The host and virus replication  
Segales and Domingo (2002) documented that, swine are the natural host for PCV-2. 
The interaction between PCV-2 and its host (domestic and wild pigs) is a complex 
process that normally begins with the attachment of the virus to the target cells and 
organs by binding to specific receptors known as glycosaminoglycans (GAG) which 
are present on the surface of the cell as shown in figure 1.6.  
The ssDNA genome enters the host cell by the help of a polyarginine peptide which is 
recognized as a cell penetrating peptide. It is transported to the nucleus and converted 
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into dsDNA by the host enzymes. Protein synthesis begins when the cap and rep 
mRNAs are transcribed and then imported to the cytoplasm. Rolling-circle replication 
(RCR) is initiated when rep/rep’ binds to the dsDNA, and introduces a nick, which 
serves as a primer and elongation of the nick leads to replication (Figure 1.6). 
Replication appears to be a slow process that occurs in several types of cells, mainly 
endothelial, epithelial cells and macrophages. (Nauwynck et al., 2012, Finsterbusch 
and Mankertz, 2009).  
 
Figure 1.6 The life cycle of PCV-2. Image adapted from Finsterbusch and Mankertz 
(2009). 
 
PCV-2 infection leads to host immunosuppression. Hematological examinations show 
a decline in the production of CD4 T lymphocytes, natural killer cells (NK cells), 
dendritic cells and B cells. The lymphoid depletion results from viral replication in the 
lymph tissues or from virus induced cellular apoptosis. The extent of lymphoid 
depletion has a direct correlation with the amount of PCV-2 antigen present in tissues 
(Júnior et al., 2012). 
1.6.2 Transmission and associated clinical manifestation  
Generally, virus transmission occurs through vertical and horizontal transmission. In 
horizontal transmission, viruses are spread between individuals of the same 
generation whereas vertical transmission happens between mother and their 
offspring. PCV-2 can be transmitted to pigs from other pigs, rodents, humans, animals, 
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pen environments and insects (Figure 1.7) (Blunt et al., 2011, Yang et al., 2012, Zhai 
et al., 2014a, Verreault et al., 2010, Alarcon et al., 2011, Lőrincz et al., 2010, Chiou et 
al., 2010, Dupont et al., 2008).  
During systemic infections of PCV-2, virus can be shed in oral and nasal secretions, 
faecal, milk, urine in naturally and experimentally infected pigs (Patterson et al., 
2011a) (Patterson et al., 2011b). The duration of the virus in swine naturally infected 
with PCV-2 at or before the age of 13 days has been shown to be at least 209 days 
after farrowing (Patterson et al., 2011a), or 69 days after experimental PCV-2 infection 
(Patterson et al., 2011b). 
 
 
Figure 1.7 Possible sources of PCV infection and cross-species spread in pigs. Image 
adapted from Zhai et al. (2014a). 
 
Shedding of the virus in the semen of adult boars is a concern for breeding herds. 
Experimentally infected boars were shown to shed  PCV-2 for at least 90 days post 
infection (Madson et al., 2008). Madson et al. (2009a) further reported that 
insemination of naïve sows with semen containing large amount of infectious PCV-2 
can lead to failure in reproduction. The transmission of PCV-2 by means of 
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insemination is dose-dependent, as semen containing lower levels of PVC-2 failed to 
infect sows (Madson et al., 2009b). 
PCV-2 coinfection with porcine reproductive and respiratory syndrome virus (PRRSV), 
which is another swine pathogen, results in increased duration and amount of PCV-2 
shedding, which contribute to a higher environmental viral load (Sinha et al., 2010). 
Airborne spread among farms in areas of high-density swine production is a potential 
concern for biosecurity. In production facilities, high levels of PCV-2 DNA (up to 107 
genome copies / m3 of air) were detected in dust particles (Verreault et al., 2010). 
Vertical transmission both in the field and experimentally were confirmed in individual 
sows (Johnson et al., 2002, Ladekjaer-Mikkelsen et al., 2001, O'Connor et al., 2001). 
Additionally, this mode of PCV-2 transmission was suggested by Bogdan et al. (2001) 
as the virus was detected in neonatal piglets. This mode of transmission may not only 
be related to reproductive failure but also to the development of multisystemic 
diseases later in the life of swine (Bogdan et al., 2001). According to Harding and Clark 
(1997), PMWS most commonly affects pigs of 2-3 weeks postweaning or at about 5-
6 weeks of age. PCV-2 viral particles are stable and persists in the environment of 
infected herds, making virus eradication very hard (Júnior et al., 2012).  
PMWS have been found to be due to dual infections with PCV-2 and other virulent 
pathogens, such as swine influenza virus, PRRSV, Porcine parvovirus, Streptococcus 
suis, Mycoplasma hyopneumoniae to mention a few. Such co-infections may confuse 
and complicate the clinical representation of the disease. The manifestation of the 
clinical signs and lesions associated with PMWS occur in a mild form in piglets infected 
with PCV-2 (Júnior et al., 2012). 
 
1.7 Diagnosis of PCV-2 
Since the disease caused by PCV-2 is a complicated disease with multiple clinical 
signs, precise diagnosis of PCV-2 infections is of paramount importance for 
implementing effective containment strategy on affected herds (Segalés et al., 2005).  
Clinical PCVAD are observed with three well established criteria: (1) observation of at 
least one clinical manifestation of the disease such as weight loss, wasting, dyspnea, 
enlargement of inguinal lymph nodes, jaundice, increased mortality or respiratory 
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signs; (2) presence of PCV-2-associated hallmark microscopic lesions in lymphoid 
tissue in the case of a dead animal; (3) detection of PCV-2 antigen or nucleic acids at 
sites of lymphoid lesions using immunohistochemistry (IHC) or in situ hybridization 
(Sorden, 2000). Analysis of histological segments for the distribution and quantity of 
PCV-2 by immunohistochemistry and in situ hybridization in affected tissues is 
regarded as the gold standard for PCVAD diagnosis  (Opriessnig et al., 2007).  
Reproductive diseases among pigs infected by PCV-2 is diagnosed with the following 
criteria: (1) late-term abortions and stillborn, sometimes with severe foetal heart 
hypertrophy; (2) the development of cardiac lesions marked by severe fibrosis and/or 
necrotizing myocarditis; (3) high levels of PCV-2 found in myocardial lesions and other 
foetal tissues (West et al., 1999). 
 
 
1.7.1 Detection of PCV-2 antibodies by enzyme immune-linked immunosorbent 
assay (ELISA) and indirect fluorescent antibody (IFA) 
ELISA in general is a sensitive technique which allows the detection and measurement 
of serum antibodies. Many commercially available ELISA kits are utilized in diagnostic 
laboratories to detect PCV-2 antigens and PCV-2 specific antibodies. There are two 
types of ELISAs for detecting PCV-2 antibodies: indirect ELISAs and competitive 
ELISAs. Briefly, indirect ELISA involves a two-binding process of primary antibody and 
secondary antibody. The antigen is bound to the micro-well plates, incubated with the 
primary antibody, washed, and then incubated with the secondary antibody prior to 
detecting by elicit of a fluorescence signal (Deng et al., 2018). The competitive ELISA 
involves competitive binding process which is performed by the sample antigen 
(original antigen) and the add-in antigen. In short, the sample antigen is incubated with 
the primary antibody. The addition of the antigen-antibody complexes to the wells pre-
coated with the same antigen then follows. Here, competition takes place since only 
less antibody will be able to bind to the antigen. The unbound antibody is washed off 
and the secondary specific antibody is added and then detection takes place. Weaker 
signal is observed when the concentration of sample antigen is high (Kong et al., 
2017). Immune peroxidase monolayer (IPM) and indirect immunofluorescence assays 
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(IIFA) were commonly used before these kits were developed to detect PCV-2 specific 
antibodies and infectious PCV-2.  
The IPM is performed by labelling the anti-species secondary antibody with 
peroxidase. The brown staining by a substrate is then observed using a light 
microscope (Zhang et al., 2016, Han et al., 2017). For the indirect 
immunofluorescence assay, the antibody is detected in body fluids by labelling the 
specific antibodies with a compound that enable them to glow with a green colour 
when observed under ultraviolet light microscopically (Meroni et al., 2019). These 
assays were however, time-consuming and require highly experienced technicians 
(Opriessnig et al., 2007, Blanchard et al., 2003b). Most commercially available PCV-
2 ELISAs are coated with an inactivated PCV-2 antigen, therefore making ELISA kits 
unaffordable for use by most pig farmers of developing countries especially. 
The IFA assay is an independent and sensitive assay which uses recombinant PCV-
2 CP for the recognition of PCV-2 specific antibodies in sera as described by Racine 
et al. (2004). IFA requires the earlier infection of porcine cells with live PCV-2 virus, a 
process which is difficult because the replication cycle is slow (Ouardani et al., 1999). 
Briefly, the sample is combined with the antigen at the acetone-fixed infected cells 
present on a slide. A  secondary indicator fluorescein-labelled antibody is then added 
and the slide is read using a fluorescent microscope, followed by the grading of the 
intensity of the signal fluorescence (Racine et al., 2004, Messenger and Rupprecht, 
2015). 
 
1.7.2 Neutralization assays and Micro-Bead Array (MBA)-based technology 
Neutralization assays are useful for detection of PCV-2-specific antibodies. However, 
it is time-consuming, needs fluorescent labelled antibodies or immunoperoxidase 
staining to verify the absence or presence of the antigen and requires a tissue culture 
laboratory to be able to carry out this specific assay (Nawagitgul et al., 2002, 
Pogranichnyyp et al., 2000).  
Other platforms for PCV diagnosis include the microbead-based assay, for example 
the Luminex® multiplex assay, a serological assay that is used to detect PCV-2 specific 
antibodies. The assay uses flow cytometry whereby colour-coded microbeads have 
different spectral addresses that enables laser-mediated detection. This diagnostic 
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involves coupling of beads to antigens or antibodies for precise detection of antibodies 
or antigens diagnostic (Lin et al, 2011; Nolan & Mandy, 2001), a process that is both 
time consuming and expensive. 
 
1.7.3 Polymerase Chain Reaction (PCR) 
Conventional PCR assays accompanied by restriction fragment length polymorphism 
(RFLP) are useful for routine and quick diagnosis. Variations in RFLP models resulted 
in the discovery of PCV-2 as a pathogen and that of PCV-2b as an emerging genotype 
(Nayar et al., 1997, Carman et al., 2006).  
Quantitative PCR (qPCR) assays that assess the number of copies of the viral genome 
as a measure of the viral load in body fluids and tissue samples have replaced the 
conventional PCR assay. qPCR is useful for detecting etiology during laboratory 
disease investigation, particularly in cases of reproductive failure where the viral load 
in the foetus is a very useful indicator. Another variation of this method is based on 
fluorescent probe-based PCRs, such as Taqman probes, which enable the detection 
of multiple PCV-2 genotypes and other pathogens in a single reaction. Diagnostic 
capacity and information availability of investigating clinical cases of PCV-2 have been 
revolutionized by fluorescence probe-based PCR assays and automated sample 
processing (Kekarainen et al., 2014). PCR is a sensitive method; however, it is highly 
laboratory laborious compared to other serological tests. In addition, this method 
confirms the presence of the virus but does not confirm the presence of the disease. 
Even though early detection and diagnosis of PCV-2 is a key step in the goal of 
elimination or reduction in the number of PCV-2 cases in developing countries, the 
majority of available diagnostic methods are expensive and time consuming. 
Therefore, there is a need for inexpensive yet effective diagnostic assays. 
 
1.8 Prevention of PCV-2 
PCV-2 can be prevented by effective control of PCVAD. Prevention of PCVAD can 
also be achieved by avoiding prompting factors through enhancing swine 
management, coinfection control and altering pig genetic background by careful 
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breeding selection of boars. It is also advisable to separate unhealthy herds which 
show clinical manifestation of PCVAD from healthy herds as soon as possible.  
Traditionally, vaccination is considered the most effective approach to manage viral 
diseases, however the duration of protection of the vaccine against the disease is 
limited (Feng et al., 2014). Even though vaccinated animals may still be infected with 
the virus, they normally have reduced viral loads compared to non-vaccinated animals. 
Therefore, at present, vaccines administered as a single-dose do not grant swine 
herds sterilizing immunity and can potentially cause evolution of the virus (Segalés et 
al., 2013, Kekarainen et al., 2010). The potential of vaccines in preventing 
multifactorial diseases such as PCVAD has prompted the intense research into and 
the production of safer vaccines as alternatives to eradicating or regulating PCV-2 
(Sun et al., 2016). 
 
1.8.1 PCV-2 vaccines  
Generally, a vaccine is a pharmaceutical composition that is safe to administer to an 
animal and can induce protective immunity against a pathogenic micro-organism. 
Since the emergence of PMWS and confirmation of the PCV-2 as its causative agent, 
researchers have been developing ways to control the virus through the development 
of vaccines. Vaccines against PCV-2 have been commercially available since 2004, 
and have led to a decrease in morbidity and improved swine production efficiency 
(Grgacic and Anderson, 2006).  
The main commercial vaccines available to date for decreasing the burden of the 
disease are derived from the PCV-2a coat protein (Opriessnig et al., 2007). These 
vaccines are highly efficient and successful in inducing humoral and cell mediated 
immunity (Fort et al., 2012, Fort et al., 2009, Kekarainen et al., 2010). Among them 
are the inactivated virus vaccines grown in different cell cultures, DNA vaccines and 
subunit vaccines containing the viral capsid proteins produced in modified insect cells 
(Karuppannan and Opriessnig, 2017a).  
The introduction of PCV-2 commercial vaccines begun in 2004. Their availability has 
led to a reduction in the disease. These vaccines are currently the best-selling 
prophylactic agent in swine farming practices (Karuppannan and Opriessnig, 2017b, 
Alarcon et al., 2013). Circovac® (Merial, France), an inactivated oil-adjuvanted virus 
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vaccine was the first to enter the market. There are three subunit vaccines that are 
based on the PCV-2 CP-encoding ORF2, expressed using the system of recombinant 
baculovirus cell expression.  These vaccines are Circumvent® (Merck, USA); Ingelvac 
CircoFlex® (Boehringer, Ingelheim USA) and Porcilis® PCV (Merck, Germany). In 
addition to these vaccines, there is Fostera® PCV (Pfizer, USA) which is an inactivated 
chimaeric PCV-1/2  that has a genomic backbone of a non-pathogenic PCV-1 and a 
CP of PCV-2 that is genetically engineered (Chae, 2012). These vaccines are 
produced based on genotype PCV-2a which shows cross-reactivity against the 
prevalent genotypes PCV-2b and PCV-2d (Karuppannan and Opriessnig, 2017b, Xiao 
et al., 2016, Carman et al., 2006).   
Although vaccinated pigs can still become infected with PCV-2, they are expected to 
have lower viral loads compared to non-vaccinated pigs hence current vaccines 
applied as single-dose protocol do not provide sterilizing immunity (Kekarainen et al., 
2010). 
 
1.8.1.1 Inactivated virus vaccines  
Generally, inactivated vaccines can be composed of either whole viruses or bacteria, 
or fractions of either while live attenuated vaccines are produced by modifying a 
disease-producing (“wild”) virus or bacterium in a laboratory. Conventional vaccines 
meant to prophylactically protect pigs against PCV-2 infection may be based on whole 
inactivated PCV-2 virus as a non-replicating immunogen (antigen) (Melanie et al., 
2019). Circovac® and Fostera™ PCV are examples of inactivated virus vaccines and 
they are for piglets that are 3 weeks and older. Drawbacks associated with inactivated 
vaccines are improper deactivation which may lead to reversal of replication and 
harmfulness. It is therefore important ensure that these viruses are effectively 
deactivated while sustaining immunogenicity, a process which can be expensive (Liu 
et al., 2016). 
 
1.8.1.2 Live-attenuated vaccines 
Suvaxyn® vaccine from Zoeitis, Netherlands (Melanie et al., 2019) is a live-attenuated 
vaccine. Normally, these vaccines are produced by propagation of the virus in a tissue 
18 
 
or cell line. The collection of the virus then follows, and its replication ability is either 
disabled physically or chemically but the antigen displaying the CP is intact. Live 
attenuated vaccines consist of a less virulent virus that can undergo partial replication 
without producing a complete disease, this can typically be achieved by altering an 
amino acid sequence of the virus. A study conducted by Fenaux et al. (2004b) has 
demonstrated the ability to produce an attenuated PCV-2 candidate vaccine in porcine 
kidney cells. In other studies by Hemann et al. (2014) and Beach et al. (2010), a 
chimaeric PCV-1/2b attenuated virus showed protection against PCV-2a and PCV-2b.   
The main draw-back with live-attenuated vaccines is the ability of their viral antigen to 
reverse to a complete virulence form. 
 
1.8.1.3 Vectored vaccines  
Viral vector vaccines are viruses that lack replication and are non-pathogenic. These 
viruses have been altered to express antigens derived from pathogenic viruses. One 
of the common approaches for viral vector vaccine production is the use of replication 
defective adenovirus. Wang et al. (2007), vaccinated pigs with a recombinant human 
adenovirus expressing the CP of PCV-2, this resulted in a specific immune response. 
In another study by Liu et al. (2013), an immune response was elicited in mice that 
were vaccinated intranasally with PCV-2 CP expressed by a non-replicating 
adenovirus. Since PCV-2 is mostly spread via nasal and oral route, these strategies 
of vaccine administration are needed. However, there is a need for further 
improvement to decrease the regularity of immunisation that is necessary. 
 
1.8.1.4 DNA vaccines 
DNA vaccines are made up of protein-encoding DNA which is administered to elicit 
cellular and humoral immunity. The plasmids normally have enhancers or promoters 
to increase the expression of the gene in the recipient of the vaccine. These vaccines 
are easier to store and transport in comparison to conventional vaccines (Krishnan, 
2000). Chimaeric PCV-1/2 DNA is among some of the initial DNA candidate vaccines. 
Its development required a non-pathogenic PCV-1 backbone in which the pathogenic 
PCV-2 CP was inserted. Pigs which were injected intramuscularly with the DNA to 
produced PCV-2 CP specific antibodies and achieve defensive immunity (Fenaux et 
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al., 2004a, Beach et al., 2010). Another study utilised combination of DNA from the 
three major ORFs as potential candidates vaccine in mice. In this study, only 
constructs consisting of ORF2 resulted in PCV-2 specific antibody responses, 
emphasizing the antigenic importance of the ORF2 encoded CP (Aravindaram et al., 
2009). Although DNA-based vaccines often have less immune potency compared to 
conventional vaccines, more research by Guo et al. (2015) and Li et al. (2015) has 
focused on either co-expressing porcine interleukin-6 or actually adding CpG motifs to 
the CP coding DNA constructs to attain an improved cellular and humoral immunity.  
  
1.8.1.5 Subunit and virus like particles vaccines 
The baculovirus-insect cell expression system has been a powerful tool in the 
development of subunit vaccines. PCV-2 CP expressed in this system have been 
shown to have immunogenic and protective properties (Blanchard et al., 2003a).These 
vaccines do not cause a disease and are not associated with side effects because 
they do not contain a live virus (Chae, 2012). Subunit vaccines has been shown to 
successfully protect pigs against PCV-2 and they are registered as a single dose to 
pigs that are about two weeks old. These vaccines have demonstrated superior 
prophylactic efficacy compared to traditional PCV-2 vaccines made from inactivated 
PCV-2 viruses (Balka et al., 2016, Weibel et al., 2012). As mentioned earlier, there are 
currently three subunit PCV-2 vaccines produced in insect cell culture expression 
systems that are commercially available. These vaccines are effective; however they 
do not produce sterilizing immunity and the virus continues to replicate and spread to 
a lesser degree (Song et al., 2007).  
It has been shown that CP recombinantly expressed using the baculovirus expression 
system  self-assembles into virus like particles (VLPs), which when used to vaccinate 
swine produced immunogenic responses (Melanie et al., 2019, Fan et al., 2007). VLPs 
are nearly identical in terms of morphology to the original virions and present an array 
of epitopes mimicking the structure of the pathogen but lack the viral genome. VLPs 
are more immunogenic than soluble CP preparations, as a result of their size and 
structure with repetitive display of immunogenic epitopes. Vaccination with VLPs 
against PCV-2 has been applied to control disease outbreaks in swine herds (Polayes 
and Hughes Jr, 1994). 
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Apart from the baculovirus expression system, other expression systems such as 
Escherichia coli (E. coli) cells, yeast and plants have drawn the attention of 
researchers in order to produce PCV-2 VLP-based vaccine candidates with improved 
efficacy and safety (Yin et al., 2010, Gunter et al., 2019).  Studies have shown the 
successful production of PCV-2 VLPs in E.coli cells that can be used as diagnostic 
agents as well as vaccine candidates (Wu et al., 2012, Zhang et al., 2014). High 
quantities of PCV-2 CP have also been expressed in Pichia pastoris and 
Saccharomyces cerevisiae yeast cells (Zhang et al., 2014, Bucarey et al., 2009). 
Vaccines produced using these expression systems are expensive due to their 
complexity requirement of bioreactors and technically skilled operator. 
Over the years, plants have gained traction as a cost-effective system to 
conventionally used expression systems. Our group was the first to successfully 
produce immunogenic PCV-2 VLPs in plants. This was the first report describing the 
expression and purification of PCV-2 CP in plants and confirmation of its assembly 
into VLPs. The VLPs have further been demonstrated to be highly immunogenic in 
mice. The yields of purified PCV-2 VLPs were approximately 2 mg/kg of fresh plant 
material (Gunter et al., 2019). This was a proof of concept study showing that plants 
can be used to make affordable and immunogenic vaccines. 
 
1.9 The role of plants in the development of biopharmaceuticals 
Recombinant proteins can be produced in various expression systems including yea
st, bacteria, mammalian cells and plants. Plants have recently become a reliable 
system for manufacturing recombinant proteins which are useful in disease 
prevention, treatment, or diagnosis.  
Plants have been occupying a vital position in biopharmacy and promised rapid 
developments in the field of plant-derived biopharmaceutical agents since 1986 
(Fahad et al., 2015, Rybicki, 2014). The production of human growth hormone in 
sunflower and tobacco tissues was the first evidence of the use of plant expression 
systems (Barta et al., 1986). In addition, Hiatt et al. (1989) successfully  demonstrated 
the use of plant-based expression for production of  a monoclonal antibody. Since 
then, a vaccine antigen of Streptococcus mutants was produced in plants (Curtis and 
Cardineau, 1990). One of the most important innovations in plant expression and 
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vaccine production is the development of an influenza vaccine consisting of 
quadrivalent VLPs by Medicago Inc. in phase II human trials, this vaccine showed 
efficacy and safety in humans (Pillet et al., 2019). Phase III results of this vaccine are 
expected to come out in 2020 with promising data. With the recent outbreak of 
Coronavirus (SARS-CoV-2), British American Tobacco is developing a potential 
vaccine produced in tobacco plants. Meanwhile Medicago Inc is pursuing a similar 
effort to combat Covid-19 which has now reached a global pandemic level. This is 
showing the relevance and strength of using plant-transient expression system in 
vaccine development. In addition, it only takes approximately 2 months to express a 
vaccine transiently in tobacco which makes it good to use especially in pandemic 
situations. 
Interestingly, the authorization of a first  plant-based enzyme substitution therapy for 
commercial use  in human by the food and drug administration (FDA) was done in May 
2012 (Fox, 2012). Gaucher’s disease is caused by a deficiency of glucocerebrosidase 
(GCD) enzyme known as Elelyso ™ which leads to the development of a lysosomal 
storage disorder (LSD). This enzyme can be produced transgenicaly in carrot cells by 
Pfizer and Protalix Biotherapeutics (Carmiel, Israel) (Shaaltiel et al., 2007).  
In 2014 during the West Africa Ebola epidemic, treatment with a triple cocktail 
consisting of antibodies (4G7, 2G4 and 13C6)  produced in Nicotiana benthamiana 
(N. benthamiana) was permitted for use to control the outbreak (Qiu et al., 2014). In 
addition, there are several plant made vaccines, antibodies, therapeutic proteins and 
diagnostic reagents that are in clinical progression such as the Norwak virus CP and 
intrinsic factor for vitamin B among others (Yusibov et al., 2011).  All these studies 
provide evidence that plant-based expression systems have the ability to produce 
affordable biopharmaceuticals for use, particularly in developing countries. 
With the high incidence of emerging viral diseases in the world, particularly developing 
countries, there is a need to focus on plant-based expression systems for the rapid 
development of vaccines. Plant-based expression systems have lower upfront 
investment costs compared to other expression systems such as insect cell and 
mammalian cell expression systems, making them suitable for deployment in 
developing countries where infrastructure cost presents an entry barrier for research, 
development and manufacturing. The use of antibiotics in livestock production has led 
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to an emergence of antibiotic-resistant pathogens. These variables have motivated 
the creation of cost-effective, scalable veterinary pharmaceutical manufacturing and 
distribution platforms. Production systems based on plants are suitable to meet these 
requirements (Sack et al., 2015, Gómez et al., 2009, Chen and Davis, 2016). It offers 
to produce the recombinant proteins in low cost biomass at large scale with yields up 
to 5 mg per kg of fresh leaves which can be subjected to processing  to obtain pure 
antigens for making vaccines (Marillonnet et al., 2005). In accordance with Chen and 
Davis (2016), the majority of commercially available vaccines are produced in 
mammalian and other cell cultures. Biopharmaceuticals produced in these systems 
however require capital intensive facilities fermenters, expensive downstream 
processing, cold storage and transportation, and sterile delivery methods. The 
development of alternative manufacturing technologies is encouraged by these 
constraints.   
There are two methods for the expression of recombinant proteins in plants, namely 
transgenic or  transient (Scotti and Rybicki, 2013). Traditionally,  plant expression 
methods depended largely on plants that are stably transformed whereby a transgene 
is incorporated into the plant’s  nucleus or plastid (Schillberg et al., 2005). Transgenic 
plants are attained via gene delivery into dicots by Agrobacterium tumefaciens or 
monocots using biolistic method (Mason et al., 1992). The system of generating 
transgenic plants is however time consuming.  
Recently, transient expression systems outperformed transgenic expression systems 
since it has a brief manufacturing time that yields high quantities of protein (Rybicki, 
2010, Schillberg et al., 2005). Transient expression systems have the ability to deliver 
target protein manufacturing in less than two months, including the time needed to 
synthesize and optimize target gene expression in plants (Musiychuk et al, 2007). 
Interestingly, it only took Medicago Inc 20 days to produce SARS-CoV-2 VLPs in N. 
benthamiana. This method involves the expression of a foreign DNA that cannot be 
inherited but is transcribed and translated within a host cell. There are two main 
methods that are regularly used to accomplish a heterologous protein's transient 
expression in crops: via viral vectors derived from Potato X virus (PVX), or tobacco 
mosaic virus (TMV)   (Sala et al., 2003, Curtis and Cardineau, 1990). When using viral 
vectors, the gene of interest is cloned into the plant virus genome, with a subgenomic 
promoter. Plants are then infected with a recombinant virus construct that carries the 
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transgene to the plant cell to produce the anticipated protein without transforming the 
plant stably (Porta and Lomonossoff, 2002). Although immunogenic proteins were 
produced with this method, the levels of protein expression were low compared to that 
of the transgenic expression system (Turpen et al., 1995, Mason et al., 1992). 
These low yields have led to the development of deconstructed plant virus vectors and 
agroinfiltration to deliver the gene of interest into plants (Marillonnet et al., 2005). The 
gene remains as an episome and it does not become a portion of the plant genome 
hence it is not passed on to the following generation. Modified plant viruses such as 
tobamoviruses, bean yellow dwarf virus, mastrevirus, geminiviruses and bromoviruses 
are regularly used. This method utilizes the viral replicative machinery to make non-
infectious vectors that can generate expression and translation of the gene of interest 
in plants (Lomonossoff and D’Aoust, 2016, Gleba et al., 2005). Another method which 
utilizes a highly translational efficiently is the non-replicating expression system which 
aims to produce high yields of  recombinant protein (Peyret and Lomonossoff, 2013, 
Hefferon, 2014). These features have enabled a scalable, flexible system to escalate 
the speed and yields of biopharmaceutical production, with time and cost reduction 
(Pogue and Holzberg, 2012, Tiwari et al., 2009). 
A variety of plant hosts such as Arabidopsis thaliana, Nicotiana tabacum and Lactuca 
sativa have been used to produce biopharmaceuticals, but tobacco plants and more 
specifically, N. benthamiana has become the preferred experimental plant species for 
the expression of recombinant proteins at industrial and laboratory scale. N.  
benthamiana is the most exceptional host, mainly due to the large number of various 
plant viruses that can infect it successfully (Goodin et al., 2008, Tremblay et al., 2010), 
furthermore they produce substantial leaf biomass and have a high soluble protein 
content (Tremblay et al., 2010).  
 
1.10 Objectives and rationale of the study 
PCV-2 is known as an emerging swine pathogen of great economic importance, 
causing significant losses in the piggery industry. Even though pig production is 
relatively small in South Africa compared to other countries around the world, it is one 
of Africa’s highest pork producers. The country currently has a pig population of more 
than 1.5 million produced commercially by more than 400 farmers. The Western Cape 
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province contributes about 11% to the country’s swine population commercially 
(Figure 1.8) (DAFF, 2018). 
 
 
Figure 1.8 The distribution of pig per province in 2017. Source: (DAFF, 2018). 
 
PCV-2 has attracted the attention of researchers since the early 1990s due to the 
economic fallout it has caused in many pig-producing countries of the world. As 
discussed previously, PCV-2 subunit vaccines are produced using baculoviral-based 
expression systems. Additionally, these vaccines rely on expensive growth media and 
sterile bioreactors for production prior to protein extraction. Since such proteins are in 
demand, it provides an opportunity for complementary production platforms to be 
explored. Moreover, plant-based transient expression systems can be promptly 
implemented and scaled up. Plants also negate contamination with animal pathogens, 
a concerning drawback with conventional eukaryotic expression systems.  
Firstly, only PCV1 and PCV2 (PCV2a, PCV2b, PCV2c, PCV2d, PCV2e, and PCV2f) 
were known, but a recently diagnosed distant porcine circovirus (PCV3) was publish
ed (Phan et al., 2016b, Chen et al., 2017, Wang et al., 2020). The recent discovery 
and characterization of PCV-3 stresses the importance of continued research and 
development of vaccines and diagnostics for PCV (Klaumann et al. (2018). This strain 
of PCV, with a genome of about 2000 bp, has been found circulating in Asia and North 
America in cases of reproductive failure, PDNS (Fan et al., 2017).  
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Since PMWS still presents a threat to emerging and backyard farmers, early detection 
of PCV-2 is of great importance. This attracted researchers’ interest to continue 
searching for affordable, reliable and fast diagnostics against PCV-2. Gunter et al. 
(2019) showed that PCV-2 VLPs can be successfully produced in plants, these 
findings have unlocked the opportunity to develop affordable plant-made serological 
assays to detect PCV-2.  Particularly because the ELISAs that are commercially 
available are expensive (approximately R18 000 per kit for 100 reactions) and must 
be imported.  
Therefore, the aim of the study is to develop a plant-made diagnostic immunoassay 
for the detection of PCV-2 antibodies in South African swine herds. The main 
objectives for this study are as follows:  
1.  To clone the PCV-2 CP gene into the pCBP-2 proprietary plant expression 
vector and compare expression levels and VLP formation to that obtained when 
using the pEAQ-HT plant expression vector, which has previously been used 
to produce VLPs (Gunter et al., 2019).  
2. Development of a lateral flow device immunoassay for adaptation to a 














2 Chapter 2: Transient expression optimisation of PCV-2 capsid protein (CP) 
in Nicotiana benthamiana 
 
2.1 Introduction 
PCV-2 has been infecting swine for many years and the leading cause of PCVAD (Wei 
et al., 2020, Chae, 2004). Over the years various expression systems has been used 
to express recombinant PCV-2 CP to manage the disease. These include insect cells, 
yeast, bacteria, plant-based and mammalian expression systems (Fan et al., 2007, 
Fan et al., 2008, Marcekova et al., 2009, Nawagitgul et al., 2002, Tu et al., 2013, Wang 
et al., 2008, Lai and Chen, 2012, Chen, 2008). In these studies, the expression of 
PCV-2 CP was achieved by optimizing the codon composition, truncating the gene to 
remove the arginine-rich N terminal, or by adding various tags that are useful for 
purification. These approaches were successful in producing full-length or truncated 
PCV-2 CP. This capsid protein is the only structural protein and the major antigenic 
determining factor of this virus. The CP has a great potential to be used as both a 
vaccine candidate and or in diagnostic assays. The PCV-2 CP has antigenic peptides 
that maximizes its capacity to be used as a diagnostic reagent and vaccine (Santos et 
al., 2018).  In addition, the CP has unique patterns on its surface that possibly helps 
with the pathogenesis, virus function and cell entry (Wang et al., 2016).  
Insect cells, yeast, bacteria, mammalian cells expression methods depend on the use 
of sterile bioreactors and expensive growth media which makes them costly and 
complex. Consequently, vaccine and diagnostic reagents produced using these 
production systems may be unaffordable and therefore do not serve their purposes in 
resource-poor countries. The increase in demand for industrially and biomedically 
useful proteins, demands highly scalable, robust, cost-effective, easy-to-use, more 
secure, and sustainable production systems.  Transient plant expression systems can 
fulfil these criteria from laboratory expression level to the industrial manufacturing of 
bioactive compounds. Plant cells carry insignificant risk of cross-contamination with 
animal pathogens and are able to carry out the necessary post-translation 
modifications and assembly of recombinant proteins (Fahad et al., 2015, Rybicki, 
2009, Diamos et al., 2016). Moreover, the prerequisites for transient expression of 
proteins in plants are a greenhouse for plant cultivation and a biosafety level-1 (BSL-
1) laboratory, making this innovative system accessible for exploration to a bigger 
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research community. Although plant expression can be either transient or transgenic, 
lately, transient expression systems have gained attention over transgenic expression 
(Rybicki, 2010). The transient expression is a contained system in itself that can be 
used to produce large quantities of proteins rapidly, thus saving time (Figure 2.1) 
(Marsian and Lomonossoff, 2016, Lico et al., 2008).  
 
 
Figure 2.1 Schematic representation of transient expression. Cloning and 
expression of the protein of interest may occur within 2-3 weeks. The image was 
adapted from Peyret and Lomonossoff (2013).  
 
A. tumefaciens is a plant and soil pathogen and is known as rhizobium radiobacter. 
This bacterium can transmit genetic information by transferring transfer DNA (T-DNA) 
into the plant nucleus carried on a plasmid that induces tumours (Ti plasmid). It 
integrates into the genome of the host causing the alteration of cells and develop into 
tumours. The proliferating tissue gives the bacterium unusual amino acids specific to 
the bacteria called opines, which are an important source of nitrogen and carbon  
(Zupan et al., 2000, Depicker et al., 1982).  
Only some of the T-DNA is incorporated into the genome, numerous copies remain in 
the nucleus as episomes whose mRNAs are translated and subsequently transiently 
expressed. A suitable expression vector is required to achieve transient expression of 
proteins in plants. The A. tumefaciens strain and expression vector used plays a vital 
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role in the plant expression speed and yield of recombinantly expressed protein. 
Generally transient recombinant expression via agroinfiltration of plant leaves is  
faster, easier, and results in higher yields of protein in comparison to transgenic plants 
(Krenek et al., 2015, Hefferon, 2014).  
The main challenges encountered with plant-produced biopharmaceuticals has been 
the low accumulation levels of some recombinant proteins within the plant cell and the 
subsequent  purification thereof (Martínez et al., 2010, Islam et al., 2019, Marques et 
al., 2019). In an effort to optimise the expression of proteins in plants, it has been 
shown that targeting heterologous proteins to a suitable intracellular compartment 
leads to higher levels of protein accumulation (Ahmad et al., 2010). The process of 
folding, assembly, post-translational modifications as well as prevention of immediate 
degradation and intervention of the protein sequences with cell metabolism can be 
directly influenced by the type of cell organelle in which the protein is found (Leite et 
al., 2019, Ahmad et al., 2010). This is because each organelle has a distinct physical 
size, protease component and biochemical environment which impact the levels of 
protein production (Streatfield, 2007, Pillay et al., 2014). Normally, recombinant 
proteins are targeted to the major compartments which includes the vacuole, the 
cytosol, the apoplast, the chloroplast and the endoplasmic reticulum (ER) using transit 
and signal peptides (Pereira et al., 2014, Miletic et al., 2016, Conley et al., 2009b).  
Notably, RNA silencing can also affect protein yield in plants. RNA silencing is known 
as a post-transcriptional gene silencing (PTGS) system which acts as a defence 
against viral infection (Waterhouse et al., 2001b, Kant and Dasgupta, 2019, Takeda 
et al., 2002). The mechanism for RNA silencing recognizes 'abnormal' RNAs, derived 
from certain double-stranded RNAs (dsRNAs), transgenes and intermediate replicants 
of viral RNAs, and breaks down homologous RNA in the cytoplasm. RNA silencing 
begins when 21-25 nucleotide small interfering RNAs (siRNAs) which corresponds to 
the target RNA are produced. Once the PTGS induction has begun at one location, 
the systemic silencing stimuli spread and eventually triggers PTGS in the rest of the 
tissues. (Waterhouse et al., 2001a). The silencing suppressor is considered to 
interfere with dsRNA-generating steps and thus inhibit silencing. Silencing 
suppressors are encoded by various plant viruses such as Tomato spotted wilt virus 
(TSWV) and Tomato bushy stunt virus (TBSV). The NSs and P19 proteins of TSWV 
and TBSV respectively were shown to suppress transgenic PTGS. Interestingly, the 
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P19 protein has shown up to 50 times greater expression for various proteins (Takeda 
et al., 2002, Voinnet et al., 2003, Margaria et al., 2015). In this study, the NSs protein 
was used. This silencing suppressor has been used widely and shown to improve 
protein expression since it increases viral siRNAs (Hedil et al., 2015, Huddy et al., 
2018).Our group was the first to transiently express PCV-2 CP in tobacco plants  
(Gunter et al., 2019). The authors used a plant-codon optimised gene, targeted to the 
cytoplasm which showed promising results.  
The knowledge of the genetic components responsible for the replication and 
expression of plant viruses has led to the creation of plant-based viral vector systems. 
One of those vectors is the newly synthesized non-replicating pCBP-2 plant 
expression vector which targets protein expression to the ER. This vector is designed 
based on the pTRAc  vector (Maclean et al., 2007). The pTRAc vector uses the 
chalcone synthase 5’ UTR which is believed to increase the translation rate, which in 
turns improves expression yield (Gallie et al., 1995). Interestingly, the 5’ UTR widely  
used and has demonstrated higher protein expression levels (Gallie, 2001, Shopan et 
al., 2020, Hinnebusch et al., 2016, Peyret et al., 2019).  
As mentioned earlier, the PCV-2 CP is not only a structural protein of the virus, but it 
is of immunogenic importance. It has potential to be utilised as a vaccine and a 
diagnostic reagent. The increasing outbreak of PMWS, especially in developing 
countries, motivates the use of CP for vaccine development and as a diagnostic 
reagent to improve management capabilities such as disease surveillance of PCV-2. 
The aim of this study was to investigate if the new plant expression vector, pCBP-2, 
resulted in higher PCV-2 CP expression levels compared to the pEAQ-HT vector 








2.2 Materials and Methods 
2.2.1 Expression vectors  
Two expression vectors were used in this study; pCBP-2, a new non-replicating 
expression vector that targets expression of proteins to the ER. The codon-optimised 
PCV-2 cp gene (GenBank accession number KJ128269) was synthesized by 
Genscript Inc (USA) and maintained in the pUC57 vector (Figure 2.2). PCV-2 cp was 
previously cloned into pEAQ-HT by (Gunter et al., 2019) (Figure 2.3 B). This vector 
targets protein expression to the cytoplasm (Sainsbury et al., 2009).   
 
Figure 2.2: A- The pUC-57 cloning vector harbouring the PCV-2 ORF2 gene. The 
PCV-2 gene is shown in the pUC57 plasmid as indicated in figure A, together with 
AgeI and XhoI restriction sites used to subclone the gene.   
 
2.2.2 Strains of bacteria and antibiotics used 
For E. coli transformation, chemically competent E. coli DH5α cells (E. cloni®, Lucigen) 
were used while for A. tumefaciens transformation the GV3101:pMP90RK and 
LBA4404 strains were utilized in this study. Recombinant E. coli and A. tumefaciens 
were cultured in the presence of specific antibiotics (Table 2.1) to sustain selective 
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pressure. All liquid cultures of E.coli were grown with agitation at 37°C overnight in 
Luria Bertani medium (LB; 0.5% yeast extract, 1% sodium chloride [NaCl] and 1% 
tryptone) as described by Sambrook et al. (1989). Agrobacterium cells were grown 3 
days on solid media plates after which they were screened for positive transformants. 
LBB (LB media with additional yeast extract (12.5 g/L) and 10 mM 
morpholineethanesulforic acid (MES)) was used for A. tumefaciens liquid culture 
growth with agitation at 27 °C. Single colonies were inoculated into 10 ml LBB for liquid 
cultures, supplemented with specific antibiotics and grown overnight. The 10 ml culture 
was used as inoculum to initiate a 50 ml culture, which in turn was used for inoculating 
500 ml LBB for large-scale infiltrations. The LBA4404 500 ml cultures were 
supplemented with 1M MgSO4 to prevent clumping of the cells. Glycerol stocks (2 ml) 
to preserve cultures were prepared by mixing the cultures with 50% glycerol in a 1:1 
ratio.  These were stored at -80 °C for later use.  
 
Table 2.1: Plant expression vectors and their antibiotic working concentrations 
in E. coli and A. tumefaciens cultures 
Vectors Strains Antibiotic Concentration 
pEAQ- HT E. coli DH5α cells Kanamycin 50 µg/mL 
LBA4404 Kanamycin 30 µg/ml 
Rifampicin 50 µg/ml 
pCBP-2 E. coli DH5α cells 
 
Ampicillin 100 µg/mL 
GV3101::pMP90RK Carbenicillin 50 µg/ml 
Kanamycin 30 µg/ml 
Rifampicin 50 µg/ml 
 
2.2.3 Subcloning into the pCBP plant expression vector 
Single colonies of E. coli DH5α transformed with pUC57-PCV-2-CP, pCBP-2 empty 
vector and pEAQ-PCV-2-CP were inoculated into 10 mL LB media supplemented with 
their respective antibiotics as indicated in Table 2.1. Plasmid DNA was extracted using 
the QIAprep® Spin DNA Miniprep Kit (Qiagen) as per manufacturer’s guidelines. All 
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DNA quantification were performed using a NanoDrop™ 2000C spectrophotometer 
(Thermo Fischer Scientific, USA). 
The PCV-2 cp gene was excised from pUC57 using the AgeI and XhoI restriction 
enzyme sites and subcloned into the pCBP-2 vector linearized with BsaI and XhoI to 
yield the pCBP-PCV-2-CP-SP construct (Figure 2.3 A). Briefly, after digesting pUC57-
PCV-2-CP and pCBP-2 with the relevant restriction enzymes (according to the 
manufacturer’s (NEB) instructions), the digested DNA was resolved on 1% agarose 
gels. The expected bands for cp and the linearized vector were excised from the gel 
and purified with the QIAquick® Gel Extraction Kit (Qiagen, USA) as instructed by the 
manufacturer.  
The pCBP-2 backbone and PCV-2 cp DNA fragment were ligated in 1:3 vector to insert 
ratio overnight at 4 °C using T4 ligase (Roche, Basel, Switzerland) as described by 
the manufacturer. The ligation mixture was transformed into chemically competent E. 
coli DH5α cells (E. cloni ®, Lucigen). Briefly, 5 µl of ligated plasmid was mixed with 15 
µl of competent cells before incubating the mixture on ice for 30 minutes. After that the 
mixture was heat shocked for 45 seconds at 42 °C then placed back on ice. Five 
hundred microlitres LB was added to the tube prior to incubation at 37 °C with agitation 
for an hour after which cells were plated onto LB agar media supplemented with 100 
µg/mL ampicillin. Single colonies were screened with vector specific primers as 
described in Table 2.2 using colony PCR.  
 
Figure 2.3: The pCBP-2 and pEAQ-HT plant expression vectors harbouring the 
PCV-2 cp gene. A- The PCV-2 cp gene was sub-cloned into the pCBP2 vector and 
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resulted in the final recombinant pCBP-PCV-2-CP-SP plasmid. B- The pEAQ-HT 
vector harbouring the PCV-2 gene (Gunter et al., 2019). 
 
A BioRad Biocycler was used to perform all PCRs. All colony PCR reactions were 
performed with Taq DNA polymerase 2x Master Mix Red ampliqon (Thermo Fisher 
Scientific), together with 0.2 µM of each primer and 2 mM MgCl2 as instructed by the 
manufacturer. The reactions were performed using the following cycling conditions: an 
initial denaturing step for 5 minutes at 95 °C, followed by 30 cycles of denaturation at  
95 °C for 30 seconds, annealing based on the temperature given in Table 2.2 for 30 
seconds, and extension for 30 seconds at 72 °C. A final elongation step followed at 72 
°C for 5 minutes. For every PCR experiment, a negative control that did not contain 
DNA template was used. The separation of all PCR products was carried out on 1% 
agarose gels stained with ethidium bromide.  O’GeneRuler™ 1kb DNA ladder from 
Thermo Fisher Scientific was used as molecular size marker. 
  
Table 2.2: Primers used in this study 
Primer name 5’-3’ primer sequence Length (bp) Tm (°C) 
FW CBP TTT CAT TTG GAG AGG ACC AG 20 51 
RV CBP GCG AAA CCC TAT AAG AAC C  19 51 
pEAQ-HTf TTC TTC TTC TTG CTG ATT GG 20 56 
pEAQ-HTr CAC AGA AAA CCG CTC ACC 18 56 
 
 
2.2.4 Transformation of A. tumefaciens 
The pCBP-2 vector, pCBP-PCV-2-CP-SP and pEAQ-PCV-2-CP were electroporated 
into their respective Agrobacterium strains as indicated in Table 2.1 based on the 
method described by Shen and Forde (1989). Briefly, in a 0.1 cm electroporation 
cuvette (Bio-Rad), 300ng of each recombinant plasmid was mixed with 100µl of 
competent Agrobacterium cells and chilled on ice for 5 minutes. Electroporation was 
carried out using a Gene Pulser Xcell™ (Bio Rad) at 200Ω, 25µF and 1.8kV. Nine 
hundred microlitres LB medium was added to the cuvettes and mixed with the cells.  
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The cell suspension was subsequently incubated at 27 °C for 2 hours with agitation 
before plating onto LB agar plates supplemented with the relevant antibiotics (Table 
2.1) and grown for 3 days. Colony PCR with relevant specific primers was performed 
as described in section 1.2.3 to confirm positive Agrobacterium clones. DNA isolated 
from positive Agrobacterium clones were back-transformed into E. coli DH5α cells to 
further verify the recombinant plasmids. Plasmid DNA from recombinant E. coli was 
digested with PstI and XhoI restriction enzymes for further confirmation. The restrict 
digests were set up according to Thermo Fisher Scientific DoubleDigest calculator and 
was incubated for 2 hours at 37 °C before resolving on a 1% agarose gel. 
 
2.2.5 Transient expression of PCV-2 CP in N. benthamiana  
2.2.5.1 Preparation of N. benthamiana plants  
All plants used in this study were grown in a plant growth room with a 16 hour light 
and 8 hour dark photoperiod and a temperature range of 18 °C (night time low) to 25 
°C (day time high), with 50-60% humidity. N. benthamiana were grown from seeds 
that were planted in trays filled with soil that was supplemented with Margaret Roberts 
supercharger fertilizer and Gaucho (0.05 g/L). Seedlings of about 2-3 weeks old were 
transplanted into individual soil-filled pots supplemented with Multi Booster fertilizer 
and Gaucho. Plants were fertilized once every week and watered every 2-3 days. Four 




2.2.5.2 Small scale expression optimization  
A preceding study in the BRU conducted by Gunter et al. (2019) focused on optimizing 
PCV-2 CP expression with the pEAQ-HT vector in N. benthamiana. In the present 
study expression of PCV-2 CP with the pCBP-2 vector was optimized to determine 
cell concentration [Optical density (OD600)] and day post infiltration (dpi) at which the 
highest levels of CP protein was expressed. The pCPB-2-CP construct was also co-
infiltrated with the pBIN-NSs (LBANSs) silencing suppressor construct to determine if 
CP yields could be improved.  
In short, 2 ml of the frozen glycerol stocks consisting of the recombinant 
Agrobacterium constructs were revived in 10 ml LBB medium consisting of specific 
antibiotics and grown with agitation overnight at 27 °C. The next day, the 50 ml LBB 
medium was inoculated with the 10 ml pre-inoculums and incubated overnight in the 
presence of appropriate antibiotic (excluding rifampicin) and 200 mM acetosyringone 
to induce the expression of the virulent genes. Cultures were prepared for syringe 
infiltration by diluting the 50 ml overnight cultures to OD600 of 0.25 and 0.5 in 
resuspension buffer (10 mM MgCl2.6H2O, 5 mM MES, pH 5.6). N. benthamiana leaves 
of 4-6 old weeks were syringe-infiltrated with the diluted cultures. Similar infiltration 
parameters were tested for the empty vector negative control, pCBP-2.  
Three leaf discs per construct were harvested at 3, 5 and 7 dpi by using the lid of a 
1.5 ml microcentrifuge tube. A volume of 200 µl DB150 extraction buffer (1 mM CaCl2, 
150 mM NaCl, 10% glycerol (v/v), 0.001% Triton X-100, 1 M Tris, 250 mM L-Arginine, 
pH6.5) supplemented with cOmplete™ Protease Inhibitor (EDTA-free) was added to 
the leaf discs and these were subsequently homogenised with a micropestle. The 
extracts were clarified at 11 142.9 × g for 5 minutes using a benchtop microcentrifuge. 
The supernatant was recovered and denatured at 95 °C in the presence of sample 
application buffer (SAB, 0.5 M EDTA, 25% (v/v 0,001% (w/v) bromothymol blue, 5% 
(w/v) SDS, glycerol) for 10 minutes and stored at -20 °C. 
 
2.2.6 Protein purification using density gradient ultracentrifugation 
Expression was scaled up in order to produce enough biomass for purification. 
Vacuum infiltration for medium scale expression optimization was carried out as 
described earlier in section 1.2.5.1 except that the 50 ml overnight culture was further 
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scaled up by to 500 ml supplemented with the relevant antibiotics (except rifampicin) 
and acetosyringone and incubated at 27°C overnight. N. benthamiana plants were 
vacuum infiltrated at -90 kPa by submerging the plants into the bacterial suspension 
and quickly releasing the vacuum. The leaves were harvested collectively at 3 and 5 
dpi and weighed. Fresh biomass was homogenised in 2 x volumes of DB150 buffer and 
protease inhibitor using a T25 digital ULTRA-TURRAX® homogenizer (Sigma-
Aldrich®). The homogenate was incubated for 60 minutes at 4 °C before clarification 
with centrifugation for 20 minutes at 8000 × g. 
The clarified crude extract comprising of the PCV-2 CP was filtered through four layers 
of 22-24 µm Miracloth® (Millipore Sigma) prior to loading onto sucrose gradients. 
Sucrose solutions were prepared in DB150 buffer. The gradients consisted of two steps: 
6 ml 45% sucrose (w/v) overlayed onto 2 ml 65% sucrose (w/v) in 38 ml Ultra-Clear™ 
ultracentrifuge tubes (Figure 2.4). Samples were centrifuged for 4 hours at 120 000 × 
g, 4 °C using a SW32Ti rotor (Beckman). The resulting pellet was resuspended in 1 
ml of 1× phosphate buffered saline (PBS, pH 7.4) and subsequently analysed (Gunter 
et al., 2019). 
  
Figure 2.4: Set up of sucrose gradient purification of plant produced PCV-2 CP 
protein. Photo and schematic representation (A and B respectively) of a discontinuous 





2.2.7 SDS-Page and western blot analysis 
SAB was added to the PCV-2 CP at a final concentration of 1×, before denaturation at 
95 °C for 10 minutes. Denatured PCV-2 CP was resolved at 120V on 12.5% SDS-
PAGE gels and either stained at room temperature overnight in Coomasie blue stain 
(48% v/v methanol, 0.1% (w/v) brilliant blue G-250, 15% v/v glacial acetic acid) and 
destained (10% v/v glacial acetic acid, 30% v/v methanol) at room temperature 
overnight; or protein expression was analysed on western blots.  For western blot 
analysis, proteins were transferred onto nitrocellulose membranes pre-soaked in 
transfer buffer (2.93 g glycine, 5.82 g Tris base, 200 mL methanol in 1000 mL water, 
pH 9.2) with a semi-dry  TransBlot® system, (Bio-Rad) at 15V for 90 minutes. After 
transfer, membranes were washed in blocking buffer (5% long life fat-free milk, 1x 
PBS, 1% Tween-20) with agitation for 30 minutes at room temperature. PCV-2 CP 
rabbit antisera diluted in blocking buffer (1:1000) was used to probe the membranes 
by incubating overnight with agitation at 4 °C. Blots were washed 4× 15 minutes in 
blocking buffer after which they were incubated in 1: 5000 dilution of the secondary 
antibody (alkaline phosphatase conjugated anti-rabbit, Sigma-Aldrich®) in blocking 
buffer at 37 °C for 60 minutes with shaking. Following incubation in the presence of 
the secondary antibody, the blots were washed 4x 15 minutes with blocking buffer 
without milk. Finally, 5-bromo-4-chloro-3-indoxyl-phosphate (BCIP) and nitroblue 
tetrazolium (NBT) phosphatase substrate (BCIP/NBT 1-component) was added to the 
blots for 30 minutes for detection of the PCV-2 CP. 
 
2.2.8 Protein quantification 
In order to quantify PCV-2 CP, gel densitometry was utilised with Bovine serum 
albumin (BSA, (Sigma-Aldrich®)) as reference protein standard. BSA with a starting 
concentration of 1 mg/mL was diluted (2- fold) in 1x PBS (pH 7.4) to create a standard 
curve. SAB was added to 25 µl of the PCV-2 CP samples and BSA standards to a final 
concentration of 1x.  Samples were denatured for 10 minutes at 95°C and resolved on 
12.5% SDS-PAGE gels. The gels were Coomassie-stained and protein quantification 





2.3 Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
2.3.1 Confirmation of recombinant E. coli and Agrobacterium clones 
Restriction enzyme digest was successfully performed to linearize the pCBP-2 vector 
with BsaI & XhoI and yielded a 6610 bp fragment as shown by the blue arrow in figure 
2.5 A. Similarly, the PCV-2 cp was excised from the pUC57 vector using AgeI & XhoI 
restriction enzyme digests as evidenced by the presence a 712 bp fragment 
constituting cp on an agarose gel (yellow arrow, Figure 2.5 A), this band was purified 
from the agarose gel for ligation into the linearized pCBP-2 vector to yield the pCBP-
PCV-2-CP-CP-SP construct.  
Colony PCR with vector-specific primers were carried out on E. coli colonies 
transformed with pCBP-PCV-2-CP-SP,  a total number of 21 colonies were screened 
of which 4 of the colonies harboured the gene of interest, as evidenced by the 
detection of an expected band at 1071 bp for colonies 1,3 17 and 18  (purple arrow). 
Colony PCR of an E. coli colony transformed with the empty vector resulted in 
amplification of a band of approximately 423 bp (orange arrow) (Figure 2.5 B), which 
was expected since it did not contain the gene of interest. The pEAQ-PCV-2-CP 
construct was also screened along with pCBP-PCV-2-CP-SP whereby vector specific 
primers were utilized, 1 colony was screened and showed to be positive as shown by 
the purple allow in figure 2.5 B which shows the presence of the gene of interest. The 
amplified product was slightly smaller, which was expected, since the constructs were 
in different vectors and amplified with vector-specific primers and the size of the 
fragment amplified is dependent on where the primers bind in the vector backbone.   
A no DNA template PCR negative control was also carried out and as expected no 
bands were observed.  
Before transformation into A. tumefaciens, RE digests with XhoI and PstI were carried 
out for confirmation of the selected positive clone. Here, two bands of size 6596 bp 
(red arrow) and 726 bp (green arrow) were observed as expected as seen in figure 
2.6 C. Single digests of the plasmid using individual  enzymes were done to assess 
the functionality of the enzymes along with an undigested plasmid which served as a 





Figure 2.5: Cloning of PCV-2 cp into the pCBP-2 vector, colony PCR screening 
of recombinant E. coli transformants and RE digest confirmation. A) Gel after the 
excision of the expected 712 bp PCV-2 cp digested with AgeI and XhoI (yellow arrow) 
from the backbone of the pUC-57 vector not excised (visible band). The pCPB-2 vector 
was linearized with BsaI and XhoI giving rise to a 6610 bp as indicated with the blue 
arrow. B) Colony PCR confirmation of successful E. coli transformants. Positive clones 
harbouring the gene of interest is indicated by the purple arrow at approximately 1071 
bp. The orange arrow at approximately 423 bp indicates the empty vector and for the 
PCR negative control, no DNA fragments were amplified. C) Double digest (PstI and 
XhoI) of the pCBP-PCV-2-CP-SP plasmid yielding two bands; 6596 bp (red arrow) and 
726 bp (green arrow) which were expected. Single digests with each enzyme gave 
rise of the expected band size along with the undigested plasmid, respectively. M – 
molecular weight marker shows fragment sizes in nucleotide base pairs (O’GeneRuler 
1kb ladder). 
 
Following confirmation of positive pCBP-PCV-2-CP-SP clones in E. coli, plasmid DNA 
was extracted and used to transform A. tumefaciens GV3101::pMP90RK. Colony PCR 
with vector specific primers was carried out as described for the E. coli clones above 
and all the A. tumefaciens colonies screened were shown to contain the gene of 
interest as indicated by amplification of a band of approximately 1071 (Figure 2.6, 
black arrow). An A. tumefaciens colony transformed with the empty pCBP-2 vector 
yielded a band of approximately 423 bp (grey arrow) after colony PCR as expected 
(Figure 2.6). Just like for E. coli screening, colony PCR of pEAQ-PCV-2 CP 
transformants were also carried out for confirmation of the A. tumefaciens clones.  
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Here, the amplified product appeared to be was slightly smaller as expected.  A no 
DNA template PCR negative control was carried out and as expected no bands were 
observed after amplification (Figure 2.6).  
 
Figure 2.6 A. tumefaciens colony PCR confirmation. Positive clones harbouring 
the gene of interest is indicated by the black arrow at approximately 1071 bp. The grey 
arrow at approximately 423 bp indicates the empty vector and for the PCR negative 
control no DNA fragments were amplified. M – molecular weight marker shows 
fragment sizes in nucleotide base pairs (O’GeneRuler 1kb ladder). 
 
2.3.2 Optimization of protein expression in N. benthamiana 
To assess plant-based transient expression as a tool for producing PCV-2 CP that is 
suitable for making an affordable PCV-2 diagnostic reagent, which will be especially 
useful in developing countries, optimization was performed to determine the day post 
infiltration and cell density at  which the best protein expression was achieved.  
Small-scale expression studies of PCV-2 CP was first conducted where plants were 
syringe-infiltrated at different cell densities with the recombinant Agrobacterium 
constructs and biomass was harvested for analysis at 3, 5 and 7 dpi.  
Figure 2.7 shows images of the phenotype of plant leaves expressing PCV-2 CP when 
infiltrated at a cell density of OD600=0.5 and 0.25 as observed at 3, 5 and 7 dpi 
respectively (Figure 2.7 A-C) and empty vector (Figure 2.7 D). Plants infiltrated with 
the recombinant pCBP-2-PCV-2-CP-SP construct developed necrosis from 5 dpi 
onwards with browning and drying out of the leaves, the negative control empty vector 
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plant was still healthy at 7 dpi.  No difference in phenotype was observed between the 
two cell densities tested.  
 
 
Figure 2.7 Phenotype of plant leaves infiltrated with pCPB-PCV-2-CP-SP. A-C) 
leaves of PCV-2 infiltrated at OD600 0.25 and 0.5 examined at 3, 5 and 7 dpi 
respectively. D) empty vector representative. 
 
Since the plants were severely necrotic from 5 dpi onward, which resulted in a loss of 
biomass and potentially reduced protein expression and resulted in protein 
degradation, co-infiltration with the pBIN-NSs silencing suppressor was carried out to 
determine if it would improve both phenotype and protein accumulation levels. The 
usage of viral gene-silencing suppressors may enhance the transient expression of 
heterologous proteins (Burgyán, 2008, Takeda et al., 2002). RNA silencing functions 
as an antiviral defensive strategy in plants. Co-expression with the NSS silencing 
suppressor showed significant improvement of the symptoms previously observed 
(Figure 2.7), and biomass appeared to be relatively healthy, with the development of 
chlorosis at 7 dpi (Figure 2.8). No significant difference in phenotype was observed 





Figure 2.8 Phenotype of plant leaves co-infiltrated with a silencing suppressor. 
A-C) leaves of pCBP-PCV-2-CP-SP co-infiltrated with a silencing suppressor at OD600 
of 0.25 and 0.5 examined at 3, 5 and 7 dpi, respectively. D) empty vector 
representative. 
 
Biomass was collected for analysis at 3 and 5 dpi of plants infiltrated at both OD 0.25 
and 0.5, with or without the presence of the NSs silencing suppressor. CP expression 
was analysed on western blots probed with either rabbit-raised PCV-2 antisera or 
mouse PCV-2 antisera.  Non-specific binding of the antibodies to host cell proteins in 
the crude extracts were observed on the western blots, which made it difficult to 
reliably detect the expressed CP protein in crude extract obtained from leaf discs. Pre-
absorption of the rabbit PCV-2 antisera with crude plant extract was also carried out 
prior to detection of CP on western blots, however no significant difference was 
observed (results not shown).  
Therefore, medium scale expression was carried out where more plants were vacuum 
infiltrated, and protein was purified to remove contaminating plant proteins. Plants 
were infiltrated with at ODs of 0.25 and 0.5 in the presence or absence of the NSs 
silencing suppressor and harvested at 3 and 5 dpi. PCV-2 CP was extracted in DB150 
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buffer and purified on discontinuous sucrose gradients, the protein was concentrated 
in the pellet and resuspended in 1× PBS (pH 7.4) and subsequently analysed on 
Coomassie-stained gels (Figure 2.9 A) and western blots (Figure 2.9 B). The empty 
vector negative control was purified and analysed using the same methods. On both 
the Coomassie-stained gels and western blots probed with rabbit-raised PCV-2 
antisera successful expression of the CP was confirmed with the detection of a band 
at approximately 27 kDa (blue arrow). Based on the intensity of the bands detected, 
the highest overall protein expression was observed at 3 dpi at both cell densities 
tested.  Infiltration at a cell density of 0.5 in the presence of the silencing suppressor 
resulted in higher CP accumulation at 3 and 5 dpi, compared to infiltration at an OD of 
0.25 as evidenced on the Coomassie-stained gel (Figure 2.9 A). The absence of the 
silencing suppressor negatively impacted both the health of the biomass (Figure 2.7) 
as well as protein expression levels (Figure 2.9). No bands were observed in the 
negative control (empty vector). The experiment was repeated two times to validate 
the results obtained.  
 
Figure 2.9 Optimization of plant-produced PCV-2 CP. A) Coomasie-stained SDS-
PAGE gel of PCV-2 CP; B) Western blot analysis of PCV-2 CP probed with rabbit 
PCV-2 antisera (1:1000 dilution) and anti-rabbit IgG alkaline phosphatase-conjugated 
secondary antibody (1:5000 dilution). Samples were analysed at OD600 0.25 and 0.5, 
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with or without a silencing suppressor (NSs or No NSs), biomass was harvested at 3 
and 5 dpi.  Labels: M: PageRuler TM pre-stained protein standard in kilodaltons (kDa), 
Blue arrow: PCV-2 CP (~27 kDa), -ve: Negative control (pCBP-2 empty vector). 
 
2.3.3 Large scale purification of pEAQ-HT and pCBP-2 – produced PCV-2 CP 
PCV-2 CP was previously successfully expressed by Gunter et al. (2019) with the 
pEAQ-HT plant expression vector and a reasonable amount of recombinant protein 
was obtained. The aim of the present study was to determine if expression levels could 
be further improved upon by using the new plant expression vector, pCBP-2.  
Based on the results obtained from the medium-scale expression studies, large scale 
expression and purification of PCV-2 CP was carried out by infiltrating plants with 
pCBP-PCV-2-CP-SP at an OD600 0.5 with the silencing suppressor as described in 
section 1.3.2.  Biomass was harvested at 3 dpi.  At the same time, plants were also 
infiltrated with pEAQ-PCV-2 CP at an OD600 of 1.0 and harvested at 4 dpi as per 
previous optimization by Gunter et al. (2019).  Biomass infiltrated with pCBP-2-PCV-
2-CP-SP and pEAQ-PCV-2 CP was purified using the same method to ultimately 
compare which vector resulted in the highest expression levels of PCV-2 CP.  Figure 
2.10 shows a Coomassie-stained gel and a western blot probed with rabbit-raised 
PCV-2 antisera. Based on the detection of bands at approximately 27 kDa (blue 
arrow), the pCBP-PCV-2-CP-SP construct that targets protein expression to the ER 
yielded the best expression levels compared to pEAQ-PCV-2-CP based on the band 
intensity observed. The band size of pCBP-PCV-2-CP-SP appears to be slightly higher 
which is possibly due to the presence of a signal peptide on the pCBP-2 vector which 
might have added extra amino acids to the N-terminal of the PCV-2 CP. As expected, 





Figure 2.10 Comparison of pCBP-2 and pEAQ-HT expression of plant-produced 
PCV-2 CP. A- Coomasie Blue stained SDS-PAGE gel of PCV-2 CP, B- Western blot 
analysis of PCV-2 CP probed using rabbit PCV-2 antisera (1:1000 dilution) and anti-
rabbit IgG alkaline phosphatase-conjugated secondary antibody (1:5000 dilution), M: 
pre-stained protein standard (kDa), -ve: Negative control (pCBP-2 empty vector).   
 
2.3.4 Quantification of PCV-2 CP 
The yields of the expressed PCV-2 CP produced in plants with the two different plant 
expression vectors were quantified using gel densitometry. BSA standard curves were 
generated from which the unknown protein concentrations were calculated (Figure 
2.11). Resuspended pellets from the sucrose gradients were analysed on a Coomasie-
stained gel together with the 58 kDa BSA reference protein prepared at a two-fold 
dilution. For both pCBP-2 and pEAQ-expressed PCV-2 CP bands were detected at 
the expected size of approximately 27 kDa (Figure 2.11 A and D). A total CP yield (per 
kg fresh weight [FW]) at least 18.15 mg/kg FW and 8.39 mg/kg FW were obtained for 




Figure 2.11 Analysis of acrylamide gel stained with Coomassie Brilliant Blue by 
densitometry. The quantification of plant expressed pCBP-PCV-2-CP-SP and pEAQ-
PCV-2-CP (A and D, respectively) assessed through densitometry evaluation of the 
appropriate band. The marker used for A is the Colour Prestained Protein Standard 
Ladder while for B is the PageRulerTM Plus Prestained Protein Ladder. Each BSA 
standard concentration is indicated above the lane (A & D). The determined 
absorbance (signal) is shown in the table for each standard and sample (B & E). C 
and F shows standard curves of BSA protein concentration. The equations were used 
for quantification of recombinant plant produced pCBP-PCV-2-CP-SP and pEAQ-













The objective of this study was to assess plant-based transient expression as a tool 
for producing PCV-2 CP that is suitable for making an affordable PCV-2 diagnostic 
reagent, especially useful in developing countries. Thus far, only one study has 
focused on the development of PCV-2 VLPs in plants using pEAQ-HT as a plant 
expression vector (Gunter et al., 2019). This has led to the rise of this study, which 
explored the expression of PCV-2 CP using the pCBP-2 plant expression vector.  
The PCV-2 viral CP has been shown to be the most important part of the PCV-2 
genome because of its immunogenic properties and capabilities to serve as a reagent 
in diagnostics. Recombinant protein production systems such as yeast, bacterial cells 
and insect cells have demonstrated promise for the development of PCV-2 CP capable 
for use as a vaccine or in diagnostics (Xi et al., 2016, Wu et al., 2012, Nainys et al., 
2014, Zhang et al., 2020b). In recent years plants have been utilised to produce a wide 
range of important proteins used to manage diseases such as influenza, cervical 
cancer, rabies, Ebola, HIV, African horse sickness, African swine fever etc.  (Tsekoa 
et al., 2020). PCV-2 CP has previously been successfully expressed in N. 
benthamiana with promising results, this was the initial step towards the aim of 
producing a cheaper PCV-2 vaccine (Gunter et al., 2019).  
In the current study, expression of recombinant PCV-2 CP in N. benthamiana was 
optimized by testing the new pCBP-2 plant expression vector.  To this end we 
evaluated the optimal Agrobacterium cell concentration for infiltration, the ideal day of 
leaf harvesting as well as the effect of co-expression with or without the NSs silencing 
suppressor on CP expression levels. The pCBP-2-expressed protein was partially 
purified to enable detection on Coomasie-stained gels and Western blots (Figure 2.9).  
In previous studies it has been shown that the cell density used for infiltration can 
influence protein expression levels (Wroblewski et al., 2005), therefore in this study, 
plants were infiltrated with the recombinant constructs at an OD600 of 0.25 and 0.5 to 
determine at which cell density the highest protein expression occurred. Protein 
analysis at OD600 of 0.5 had a better yield compared to OD600 of 0.25 at 3 dpi while at 
5 dpi OD600 of 0.25 had a better yield (Figure 2.9). These results were inconclusive 
since severe necrosis was observed across the two ODs (Figure 2.7) which has 
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potentially affected the expression. For this reason, the PCV-2 CP was co-expressed 
with a silencing suppressor to potentially improve the expression.  
RNA silencing is known in plants as a post-transcriptional gene silencing (PTGS) 
system which acts as a defence against viral infection (Waterhouse et al., 2001b, Kant 
and Dasgupta, 2019, Takeda et al., 2002). The mechanism for RNA silencing 
recognizes 'abnormal' RNAs, derived from certain double-stranded RNAs (dsRNAs), 
transgenes and intermediate replicants of viral RNAs, and breaks down homologous 
RNA in the cytoplasm. RNA silencing begins when 21-25 nucleotide small interfering 
RNAs (siRNAs) which corresponds to the target RNA are produced. Once the PTGS 
induction has begun at one location, the systemic silencing stimuli spread and 
eventually triggers PTGS in the rest of the tissues. (Waterhouse et al., 2001a). The 
silencing suppressor is considered to interfere with dsRNA-generating steps and thus 
inhibit silencing. The silencing suppressor used in this study was NSs which is derived 
from TSWV (Margaria et al., 2015, Takeda et al., 2002). This silencing suppressor has 
been used widely and shown to improve protein expression since it increases viral 
siRNAs (Hedil et al., 2015, Huddy et al., 2018). 
CP was successfully expressed with the pCBP-2 vector, with the highest protein 
accumulation levels obtained when plants were co-infiltrated with the pBIN-NSs 
silencing suppressor construct at an OD600 of 0.5 and harvested at 3 dpi. Co-
expression with the silencing suppressor protein resulted in significantly increased 
accumulation of PCV-2 CP (Figure 2.9), with a significant improvement of the health 
of the plant (Figure 2.8). Protein expression levels observed after co-expression with 
NSs, resembled findings shown by Gunter et al. (2019) in which plants infiltrated with 
the pEAQ-HT vector, which contains the P19 silencing suppressor on the same T-
DNA as the gene of interest (Sainsbury et al., 2009), resulted in very little development 
of chlorosis and necrosis (Gunter, 2017).  
As the overall aim of this study was to produce a plant-made diagnostic reagent for 
PCV-2 based on the CP, we had to determine which plant expression vector would 
give the highest yields of PCV-2 CP. In order to achieve this, large scale expression 
studies were carried out with the recombinant pCBP-2 and pEAQ-HT constructs.  
Biomass was partially purified on discontinuous sucrose gradients and overall protein 
yield was determined with gel densitometry (Figure 2.11). A 2-fold higher yield of CP 
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was obtained with the pCBP vector (18 mg/kg) compared to yields obtained from 
pEAQ-HT (8 mg/kg). The difference in protein levels achieved by the two vectors 
could be attributed to localisation within the plant cell compartment.  The increase in 
recombinant protein yield is highly improved by targeting proteins to specific cellular 
compartments for isolation and post-translational modifications (Maclean et al., 2007).  
The pCBP-2 vector directs protein to the ER while the pEAQ-HT vector targets protein 
expression in the cytoplasm (Sainsbury et al., 2009). Based on the results obtained in 
this study, the amount of protein expressed using the pCBP-2 vector is ~two-fold 
higher than when expressed with the pEAQ-HT vector and it might be because in the 
cytoplasm the protein is more exposed to proteases which can degrade the protein, 
whereas in the ER the protein is protected by membranes (Schwarz and Blower, 
2016). The presence of the signal peptide on pCBP-2 may result in continuous 
interaction with ER chaperones to promote proper protein folding (Benchabane et al., 
2008), a low level of proteolytic activity (Vitale and Pedrazzini, 2005) or a stabilizing 
effect of glycosylation in the ER compartment (Floss et al., 2009). Similar results have 
been described earlier for other recombinant proteins expressed in N. benthamiana. 
Miletic et al. (2016) obtained low levels of the tailspike protein Gp9 accumulation when 
targeted to other compartments compared to the ER. Another study has demonstrated 
higher subcellular accumulation of polygalacturonase when targeted to the ER in 
comparison to other compartments (Pereira et al., 2014). Notably, since the ER is the 
most suitable organelle for post-translational modifications, ER targeting has usually 
been associated with increased yields of recombinant proteins in plants (Tschofen et 
al., 2016, Conley et al., 2009a).  
It has also been observed (Figure 2.10) that the size of the ER-targeted PCV-2 CP is 
slightly higher than the cytoplasm-targeted PCV-2 CP which is likely due to the 
additional sequence of the leader peptide derived from the murine heavy chain of 
mAb24 (LPH signal peptide) which is present in the pCBP-2 expression vector. The 
signal peptide may add extra amino acids sequences to the N-terminal of the PCV-2 
CP hence an increase in the size may occur. Similar results were obtained in a study 
by Pêra et al. (2015) where the VP6 protein of Rotavirus was targeted to various 
compartments such as the cytoplasm, chloroplast, ER and apoplast and a higher 
molecular weight band was observed for VP6 protein targeted to the ER.  
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Even though the CP yield obtained using the pEAQ-HT vector in this study was lower 
than that of the pCBP-2 vector, we showed improved protein yields compared to a 
previous study by (Gunter et al., 2019) which utilized the same vector where only ~2 
mg/kg FW CP was produced (Gunter et al., 2019). Although the infiltration conditions 
and the purification conditions were exactly the same as that of the previous study, 
this variation could be attributed to factors such as plant handling during infiltration, 
time of harvest and purification, storage of the protein as well as the growth conditions 
of plants (Fahad et al., 2015).  
In conclusion, the CP encoded by ORF2 of the PCV-2 genome was successfully 
expressed in N. benthamiana using the novel pCBP-2 plant expression vector. Here 
we found that the pCBP-2 vector can be utilized to achieve high yields of PCV-2 CP 
compared to the previously used pEAQ-HT vector. The study serves as a major initial 
step towards the aim of transiently producing the PCV-2 CP in N. benthamiana with 
improved yield, which may potentially be useful as an immunogenic protein of 
biomedical and industrial importance. To the best of our knowledge this is the first 



















The ability to predict, monitor, and manage the spread of porcine circoviruses is not 
only vitally important for veterinary observations but also plays a significant role in the 
surveillance of human diseases resultant of zoonotic viruses.  
Since clinical and epidemiological data is usually limited during the emergence of 
diseases caused by viruses, it is extremely important to be able to track the spread of 
the culpable virus and to record the manifestation and clinical symptoms associated 
with that specific disease. Early diagnosis of the pathogen responsible for the disease 
is the most important step in managing diseases of any sort as this allows proper 
implementation of appropriate preventative measures in unaffected animals, and 
limitation of further spreading thereof. In addition, proper diagnostic procedures of viral 
diseases are essential to monitor disease progression. In general, diagnosis of viral 
diseases are hindered by the lack of reagents for identifying the viral antigen in 
suspected cases for use serology-based studies (Boivin et al., 2016, Burbelo et al., 
2019). This is the same with PCV-2, which is one of the major burdens within the pig 
industry, especially in developing countries. The lack of diagnostic assays can be 
resolved by developing quick yet effective diagnostic techniques that do not 
necessitate specialized expertise, equipment, and facilities in comparison with assays 
that require viral culture, that is still a pillar of viral diagnosis.  
The CP of PCV-2 has been demonstrated to be highly immunogenic in infected hosts 
which makes it an effective vaccine candidate. Globally, strict PCV-2 vaccination 
procedures have led to effective control of both the virus and its related diseases in 
swine (Afghah et al., 2017, Chae, 2016, Wozniak et al., 2019). The PCV-2 CP elicits  
specific antibody responses in swine, therefore making it an ideal target for PCV-2 
serology-based diagnosis (Nawagitgul et al., 2000). The choice of utilising the ORF2 
CP and not the ORF1 protein (Rep protein) is based on certain factors such as the 
ability of the CP to attach itself to host receptor and activation of an immune response 
(Nawagitgul et al., 2002, Saporiti et al., 2020b, Melanie et al., 2019, Kim et al., 2018).  
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In the course of PCV-2 infection, antibodies are made against the three proteins (Rep, 
ORF3 and CP) , but mostly to the abundant CP (Juhan et al., 2010, Peng et al., 2016). 
The potential to detect antibodies elicited against the CP in the infected host's serum 
makes it possible to diagnose present or previous infection as well as viral exposure.  
Recombinantly expressed CP has the ability to self-assemble into structures referred 
to as VLPs which are immunogenically and structurally identical to native virions 
(Bucarey et al., 2009, Fan et al., 2005, Duan et al., 2019, Liu et al., 2012, Gunter et 
al., 2019, Liu et al., 2020, Chae, 2012). The potential to produce VLP-based vaccines 
in yeast, insect and bacterial cell-based systems that have the ability to elicit cell 
mediated and humoral immunity in animals has provided a platform to utilise the same 
foundation for the development of a highly specific diagnostic tool (Xi et al., 2016, 
Nainys et al., 2014, Chae, 2012).  
There are different methods to diagnose PCV-2 infections in swine herds, these 
include qPCR, indirect fluorescent antibody tests (IFATs) and ELISAs. Currently there 
are two commercially available kits used to diagnose and manage PCV-2. The PCV-
2 antigen test kit (qPCR) enables the detection and quantification of PCV-2 DNA which 
provides information about the viral load of the virus depending on the 
presence/absence of the virus (https://www.biochekbulletin.com/wp-
content/uploads/2015/06/MZ-16390-BIOCHEK-Folder-PCV2_V1.0_web.pdf). On the 
other hand, the PCV-2 antibody test kit (ELISA) detects IgG antibodies in swine sera 
elicited by all strains of PCV-2. In this ELISA, the plates are coated with inactivated 
virus which can be bound by antibodies present in sera, the results of the test are 
quantitative. Furthermore, the test provides important information such as antibody 
titres after vaccination or infection with field virus, the uniformity of immunity and the 
optimal vaccination time. Additionally, the test can detect antibodies as soon as 14 
days post vaccination/infection (https://www.biochek.com/swine-elisa/porcine-
circovirus-type-2-antibody-test-kit/). Although diagnosis based on clinical symptoms 
manifested is widely used, performing PCV tests among the swine population is an 
important aspect in diagnosis since asymptomatic infection in swine is widespread 
(Patterson et al., 2011c). Additionally, proper preventative measures can then be put 
in place based on the results obtained from testing.  
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With an increase in viral diseases across the globe, the use of lateral flow devices in 
diagnostics has been explored over the years since it is a rapid testing method which 
allows faster decision making. The use of such devices enables early stage diagnosis, 
observation, and treatment of diseases. In addition, these tests can be used with little  
training and requires less time to perform (Koczula and Gallotta, 2016, Sigmund et al., 
2018, Soh et al., 2020).  
To obtain recombinant proteins that is of industrial and biopharmaceutical importance, 
the purification method that allows efficient processing is of paramount importance. 
Several methods for the purification of PCV-2 VLPs have been studied to ensure that 
the protein is efficiently separated from other cellular material in the extract and that 
VLPs are free of contaminants. Fully assembled PCV-2 VLPs of high purity were 
obtained when using ion-exchange chromatography (Xi et al., 2016, Masuda et al., 
2018, Zaveckas et al., 2015, Lin et al., 2019), or affinity tag columns accompanied by 
size-exclusion chromatography (Wu et al., 2016, Trundova and Celer, 2007, Yang et 
al., 2019) for purification.  Although these methods are effective for purifying the 
protein of interest, they require the addition of affinity tags to the protein and 
chromatography columns which adds additional costs for overall protein production 
and purification. Moreover, production becomes more complex since the affinity tags 
have to be removed after protein purification since its presence might present a 
disadvantage for the use of the protein, especially in clinical application (Arnau et al., 
2006, Mahmoodi et al., 2019). PCV-2 VLPs produced in different expression systems 
have been purified successfully over the years using a simple separation technique 
known as density gradient ultracentrifugation. This method is a preparative technique 
that is not scalable for commercial production (Khayat et al., 2019, Nainys et al., 2014, 
De Almeida et al., 2017, Wu et al., 2012, Gunter et al., 2019).  
Several studies have investigated the potential to develop IgG PCV-2 VLP-based 
ELISAs to detect PCV-2 IgG specific antibodies in swine sera. However, these studies 
used costly expression systems such as yeast, insects and E. coli to produce VLPs 
(Blanchard et al., 2003b, Nainys et al., 2014, Ilha et al., 2020). For this reason, there 
is a need to explore a cheaper and simpler expression system to produce VLPs that 
can potentially be used as a coating reagent in serological assays, such as ELISAs, 
which will in turn lower the production costs and ultimately the costs of the final testing 
kit. Recently, a Covid-19 diagnostic reagent was successfully expressed in plants for 
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use in RT-PCR, indicating the relevancy of plant-based expression system (Chan et 
al., 2020). There is also the potential to use these VLPs for the development of lateral 
flow devices which may help with faster diagnosis and better management of the 
disease. These lateral flow devices can be used in real time by farmers as it does not 
require expertise to read the results. 
In the work described in this chapter, the production of plant-expressed PCV-2 VLPs 
was optimised. This involved the cloning of the PCV-2 cp gene into the pCBP-2 vector 
(Chapter 2), lacking an ER-targeting signal peptide. Methods based on density 
gradient centrifugation and Ion exchange chromatography (IEC) were also optimised 
for the purification of VLPs from plants. Purification of high yields of PCV-2 VLPs from 
N. benthamiana is a crucial first step towards producing a plant-made coating reagent 
for the development of an ELISA-based diagnostic assay. Furthermore, E. coli 
expressed VLPs were also produced and both the transiently expressed VLPs and E. 
coli made VLPs were used as a coating reagent in the development of a lateral flow 














3.2 Material and methods 
3.2.1 Cloning  
The purpose of this chapter was to optimize the production of PCV-2 VLPs.  Several 
attempts were made to produce VLPs using the previous construct (pCBP-PCV-2-CP-
SP) (Chapter 2), with no success. It was thought that the ER signal peptide on the 
pCBP-2 vector might be hindering the formation of VLPs, this led to the design and 
cloning of a new construct without the ER signal peptide.  New forward (2019FP) and 
reverse (2019RP) primers were designed to add the BspHI site to the 5’ end of the cp 
gene and XhoI to the 3’ end of the gene (Table 3.1, restriction enzyme sites in bold 
and underlined).  The pUC57-PCV-2 plasmid DNA was used as DNA template for 
PCR amplification of cp. 
 
Table 3.1 Primers used for re-cloning 
Primer name 5’-3’ primer sequence Length (bp) Tm (°C) 
2019FP GCT CAT GAC CTA CCC CAG 
GAG GAG GT 
26 64 
2019RP CGC TCG AGT CAG GGG TTG 




PCR reactions were carried out as described in Chapter 2, section 2.2.3 with a few 
modifications. Here, Phusion® High-Fidelity DNA polymerase was used according to 
the manufacturers protocol. As done for all PCRs, a negative control that contained 
no DNA template was used. PCR products were separated on 1% agarose gels, with 
O’GeneRuler™ 1kb DNA ladder (Thermo Fisher Scientific) as size marker. 
After adding the restriction enzyme sites using PCR, the PCV-2 cp PCR fragment was 
gel purified using the QIAquick® Gel Extraction Kit (Qiagen, USA) as instructed by the 
manufacturer before digesting it using BspHI and XhoI restriction enzymes. The 
pCBP-2 vector was linearized using NcoI and XhoI. The restriction sites: BspHI and 
NcoI have compatible cohesive ends which can be ligated; however, the restriction 
sites are both destroyed after ligation. The digested cp PCR fragment and pCBP 
backbone was excised from the gels and purified using the above-mentioned gel 
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purification kit.  This was followed by overnight ligation, as described in Chapter 2, 
Section 2.2.4.  
After ligation, the ligation mix was transformed into E. coli competent cells as 
described in Chapter 2 (Section 2.2.4). Transformants were screened by PCR using 
vector specific primers (Chapter 2, Section 2.2.3, Table 2.2) and confirmed using 
restriction enzyme digestion. The recombinant plasmid was subsequently transformed 
into GV3101::pMP90RK A. tumefaciens electrocompetent cells and positive clones 
were confirmed as described above.  
 
3.2.2 Infiltration of N. benthamiana 
N. benthamiana plants were infiltrated with the recombinant pCBP-PCV-2-CP, pEAQ-
PCV-2-CP, and the pCBP-2 empty vector constructs. The pCBP-PCV-2-CP and 
pCBP-2 empty vector were co-infiltrated with pBIN-NSs at an OD600 of 0.5 each.  Time-
trials were carried out where biomass was harvested at 4, 5 and 6 dpi and analysed 
for VLP formation. The pEAQ-PCV-2-CP construct was infiltrated at an OD600 of 1.0 
and biomass was harvested at 4 dpi as described by Gunter et al. (2019).  
 
3.2.3 Purification of VLPs by ultracentrifugation 
VLPs were extracted and purified as described in Chapter 2. Briefly, after the plant 
extract was clarified with slow speed centrifugation of 8000 ×g, the supernatant was 
loaded onto discontinuous 65% and 45% sucrose gradients which were subjected to 
ultracentrifugation for 4 hours at 120 000 × g at 4 °C.  Putative VLPs were 
concentrated in the pellets which were resuspended in 1× PBS (pH 7.4) for further 
analysis. 
The resuspended pellets obtained after sucrose density gradient centrifugation were 
further purified on caesium chloride (CsCl) gradients.  To this end 4.5, 5, 5.5 and 10 g 
of CsCl were dissolved in 10 ml DB150 buffer lacking arginine (Nainys et al., 2014). 
Five hundred microlitres of each of the 4 CsCl dilutions were under layered in Thinwall 
Ultra-Clear™ ultracentrifuge tubes (Beckman) to prepare the step gradients. 
Resuspended pellets were layered onto the CsCl gradients and gradients were 
centrifuged at 4 °C for 16 hours at 180 000 × g using a Beckman SW55Ti rotor.  Five 
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hundred microlitre fractions were collected from the bottom of the tubes after 
ultracentrifugation. CsCl was removed from the samples by dialysing the samples at 
4 °C overnight in 1× PBS (pH 7.4) with stirring. 
 
3.2.4 Transmission electron microscopy (TEM) analysis    
Transmission electron microscopy (TEM) analysis was carried out to assess if the 
expressed CP had assembled into VLPs. Sucrose purified pellets of the construct with 
the signal peptide (pCBP-PCV-2-CP-SP) as described in Chapter 2 were also 
assessed for VLP formation. Briefly, carbon-coated copper grids of a 200-mesh size 
were glow discharged for 30 seconds at 25 mA using a Model 900 SmartSet Cold 
Stage controller (Electron Microscopy Sciences). The carbon side of the grids were 
floated on the samples for 4 minutes to trap samples onto the grids. Grids were 
washed 4 x with deionized water and negatively stained with 2% w/v uranyl acetate 
for 30 seconds. Grids were viewed using a FEI Tecnai 20 transmission electron 
microscope. After the construct with the signal peptide showed no VLP formation, the 
signal peptide was removed and the new construct (pCBP-PCV-2-CP) lacking the 
signal peptide was assessed for VLP formation as per the procedure above. 
 
3.2.5 Purification optimisation 
To produce VLPs for use in diagnostic assays we set out to optimise the VLP 
purification method to obtain fully assembled VLPs of high purity that were free of 
bacterial contamination.  
 
3.2.5.1 Density gradient purification 
To improve on the purity and sterility of VLPs, two methods of density gradient 
ultracentrifugation purification were explored. For the first method, VLPs were 
extracted in 1× PBS (pH 7.4) and the homogenate incubated at 4 °C for 1 hour. The 
crude extract was clarified at 8000 × g for 20 minutes at 4 °C and the resulting 
supernatant filtered through 4 layers Miracloth. The clarified crude extract was loaded 
onto discontinuous sucrose gradients consisting of 20%, 30%, 40% and 50% sucrose 
steps of 3 ml each.  Gradients were centrifuged for 18 hours at 20 000 × g, 4 °C using 
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a SW32Ti rotor. After ultracentrifugation, 1 ml fractions were collected from the bottom 
of the tubes. Fractions were analysed on Coomasie blue-stained gels, western blots, 
and with TEM. Additionally, 100 µl of each sample was plated out on LB agar media 
plates without antibiotics to observe any viable microbial growth.  
The second density gradient purification method involved extraction of the VLPs in 
DB150 buffer. Briefly, 15 g of fresh biomass was homogenised in 20 ml of DB150 buffer 
and incubated at 4 °C for 1 hour. The crude extract was clarified as described above 
and loaded onto gradients consisting of 20%, 30%, 40%, 50%, 60% and 68% sucrose 
steps of 3 ml each in DB150 buffer. Ultracentrifugation was performed at 100 000 × g 
for 15 hours at 4 °C using a SW32Ti rotor. Fractions of 1 ml were collected from the 
bottom of the tubes and analysed on dot blots and plated out on LB agar to screen for 
contamination.  
The fractions confirmed to contain PCV-2 CP with no bacterial contamination were 
subjected to a further purification step. Here, the PCV-2 CP fractions were pooled and 
loaded onto 20-50% OptiprepTM (Sigma Aldrich) gradients consisting of 1.5 ml steps 
each. OptiprepTM is a sterile gradient density medium that is endotoxin free and is 
normally used to purify and isolate macromolecules. This medium is obtained as a 
60% iodixanol stock solution. A 50% OptiprepTM stock solution was prepared by 
diluting the OptiprepTM in 6x PBS (pH 7.4), this ensures that the final buffer 
concentration in all the Optiprep™ steps are 1x. OptiprepTM steps of 40%, 30% and 
20% were prepared from the 50% stock solution diluted in 1x PBS (pH 7.4). The 
gradients were centrifuged at 120 000 × g for 2 hours using a SW32Ti rotor, 750 µl 
fractions were collected from the bottom of the tubes for analysis.  
 
3.2.5.2 Ion exchange chromatography (IEC) purification  
Biomass was harvested at 6 dpi, weighed, and homogenised in 3 volumes (weight: 
volume) 1× PBS (pH 7.4). The homogenate was filtered through 2 layers of Miracloth. 
After filtration, all downstream processing was carried out on ice or at 4 °C. The crude 
extract was split in two: for the one half the pH was adjusted to pH 4; and for the other 
half the pH was not adjusted and remained at pH 6.8 (this pH of the crude extract was 
obtained after the leaf material was homogenised in 1× PBS of pH 7.4 ). These 
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extracts were centrifuged at 8000 × g for 20 minutes at 4 °C. After centrifugation, the 
supernatant was recovered, and the exact volume was measured. 
The clarified extracts were subjected to ammonium sulphate (NH4)2SO4 precipitation.   
The desired amount of (NH4)2SO4 required for each percentage saturation was 
calculated using the online tool at http://www.encorbio.com/protocols/AM-SO4.htm.  
The pH 4-adjusted sample was treated with 80% (NH4)2SO4 while the other sample 
whose pH was not adjusted was treated successively with 20%, 30%, 40%, 50% and 
80% (NH4)2SO4. The pH 4- adjusted sample was treated with only 80% (NH4)2SO4 
because the pH drop would facilitate the removal of most host cell proteins. After each 
step of adding the (NH4)2SO4, centrifugation was carried out at 8000 × g for 20 minutes 
at 4 °C in order to recover the pellet containing precipitated proteins, the supernatant 
was kept for additional precipitation at a higher percentage (NH4)2SO4. (NH4)2SO4  was 
slowly added to the supernatants at 4 °C with constant stirring to avoid protein crash 
out. Pellets collected after centrifugation were stored at 4 °C for later evaluation. The 
precipitated pellets were each resuspended in 5 ml 0.05 M Tris buffer (pH 8), and the 
samples were subsequently dialysed overnight in 0.05 M Tris (pH 8) to remove 
(NH4)2SO4.  
The dialysed samples were centrifuged at 3730 × g for 20 minutes at 4 °C followed by 
filter-sterilization of the recovered supernatant through 0.22 µm syringe filters. The pH 
4-adjusted sample, and the 30% (NH4)2SO4 sample of the non-pH adjusted batch were 
subjected to IEC using anion exchange columns. The procedure was obtained from 
(Masuda et al., 2018) with few modifications. Briefly, samples were diluted in 50 ml 
0.05 M Tris buffer (pH 8) and the IEC column (Praesto® Jetted Q35, Purorite Life 
Sciences, UK) was washed with the same buffer to provide an equilibrium 
environment. Columns of 5 ml (5 ml = 1 column volume) were prepared and 
equilibrated with 10 column volumes of binding buffer (0.05M Tris, pH 8). After which 
the sample was loaded onto the columns. The proteins were eluted with ten steps of 
5 ml each of binding buffer (0.05 M Tris,  pH 8), containing 0.15 M, 0.3 M, 0.45 M, 0.6 
M, 0.75 M, 0.9 M, 1.05 M, 1.2 M, 1.35 M and 1,5 M NaCl each. The column was 
washed with 10 column volumes of 0.1 M sodium hydroxide for cleaning before storing 
in 20% ethanol. The eluted fractions together with the flow through and washes were 
analysed on western blots, trapped on grids for EM analysis, and plated on LB plates 




3.2.6 Production of PCV-2 VLPs in E. coli 
While the optimization of VLP production in plants was underway, PCV-2 VLPs were 
made in E. coli and trialled for their use in lateral flow devices. E. coli expression is the 
most frequently used laboratory system for the production of recombinant proteins 
because of its relatively low cultivation costs, rapid growth and increased genetic 
characterization (Chen, 2012).   
The PCV-2 cp was cloned into the pROEX-HTc vector, transformed into E. coli DH5α 
competent cells and VLP production was optimised by Gunter et al. (2019). For large 
scale expression and purification, 10 ml LB supplemented with 100 µg/ml ampicillin 
was inoculated with the pPROEX-HTc-PCV-2 construct. The same was done with the 
empty pROEX-HTc vector which served as a negative control. These constructs were 
incubated overnight with agitation at 37 °C and transferred to 50 ml LB and incubated 
as before. The following day, the 50 ml culture was diluted 1:100 and incubated with 
agitation until the OD600 reached 0.5-1.0 after 1 hour of incubation. The bacterial 
culture was induced with the non-hydrolysable lactose equivalent; isopropyl β-ᴅ-
thiogalactopyranoside (IPTG) to a final concentration of 0.6 mM. After adding IPTG 
the culture was incubated for 1 hour before centrifugation at 10 000 × g for 10 minutes 
at 4 °C, the wet pellet was weighed and stored at -80°C until further use. 
Partial purification of the PCV-2 CP was carried out according to the inclusion body 
cell extract preparation protocol of BugBusterTM (Merck, Germany). In short, the wet 
cell pellet was resuspended in the BugBuster reagent and 25 units/ml Benzonase 
(Sigma-Aldirich ®, Missouri, USA) was added to the mixture, followed by 20 minutes 
incubation at room temperature. The cell lysate was centrifuged at 16 000 × g for 20 
minutes (4 °C) and the pellet was recovered by centrifugation. The pellet was 
resuspended in BugBuster™ and 200 µg/ml lysozyme (Sigma-Aldrich®) after which 
the mixture was incubated at room temperature for 5 minutes. Following incubation, 
6× volumes of 1:10 diluted BugBuster™ was added to the suspension and vortexed 
before centrifuging at 16 000 × g for 15 minutes at 4 °C. The pellet was washed with 
1:10 diluted BugBuster™ a further two times. Following the BugBuster™ washes, the 
pellet was washed six times with 1x PBS (pH 7.4) before resuspending the final pellet 
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in endotoxin-free PBS (pH 7.4, Sigma Aldrich) and storing it at -20 °C. The final pellet 
was analysed on SDS-PAGE gels and TEM analysis was carried out. 
 
3.2.7 Lateral flow development 
After quantification of the PCV-2 protein on a SDS-PAGE gel and TEM analysis, the 
E.coli and plant-made PCV-2 VLPs were handed over to Antrum Biotech, a 
biotechnology company specialising in the development of diagnostic assays,  for the 
development of a lateral flow device (Figure 3.1).  
 
Figure 3.1 A schematic representative of a lateral flow device. Different parts of 
the device such as the sample pad, conjugation pad, membrane, and absorption pad 
are indicated. Blood sample is added to the sample pad, flows through to the 
conjugation pad where it binds to antibodies and migrate along the device. As the 
sample migrates, the binding reagents on the nitrocellulose membrane will bind to the 
antibody-antigen complex at the test line. If the target is present, a colour line will 
appear. The sample then migrates further to the absorption pad in order to absorb 
excess sample. The control line consists of affinity ligands which indicates if the 
sample flowed through. Here, a line must always show. 
 
In addition, the company was also supplied with rabbit serum obtained from rabbits 
that were immunized with E.coli-produced PCV-2 VLPs as well as IgG precipitated 
from the serum with sodium acetate (Gunter, 2017). Antrum Biotech carried out and 
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designed all the methods employed for the lateral flow device development, this 
included: antibody isolation, concentration, purity, and conjugation.  Antibodies were 
isolated using two methods; Protein A was isolated from sera using the non-gas 
chromatography (NGC) system. (NH4)2SO4 precipitation was done to obtain the IgG 
precipitated antibody. Briefly, fresh saturated (NH4)2SO4 was prepared. One millilitre 
of sera sample was diluted to 10 mL with deionised water. Ten millilitres of saturated 
(NH4)2SO4 was added to the diluted sera and the mixture shaken for 1 hour at room 
temperature. After incubation, the homogenate was centrifuged for 5 minutes at 1409 
× g using a JA-14 rotor. The pellet obtained after centrifugation was resuspended in 1 
ml of 1× PBS (pH 7.4) and then dialysed in 1× PBS (pH 7.4) before analysing the 
sample on 12.5% SDS-PAGE to confirm antibody concentration and purity.  
In order to optimize the lateral flow assay, two alternative strategies were developed 
for detecting antibodies; these were: double mix and triple mix (Figure 3.2). Briefly, for 
the double mix strategy, the lateral flow strip was coated with E. coli expressed antigen 
and the unconjugated precipitated antibody. At the same time, the anti-rabbit 
secondary antibody conjugated to biotin and strep-HRP was mixed in microcentrifuge 
tubes for 5 minutes and the mixture was applied to the lateral flow strip for detection. 
On the other hand, the triple mix strategy involved coating the strip with E. coli 
expressed VLPs together with the unconjugated precipitated antibody. Separately, 
equal amounts of unconjugated precipitated antibody plus the anti-rabbit secondary 
antibody conjugated to biotin and strep-HRP was added to the microcentrifuge tube 
and incubated for 10 minutes. After incubation the mixture was applied to the coated 




Figure 3.2: Mixing strategies. A) Double mix approach: Application of sample 
followed by pre-incubation of detection antibodies and strep-HRP. B) Triple mix 













Primers were designed to add the BspHI restriction enzyme site to the 5’ end of PCV-
2 cp to facilitate sub-cloning into pCBP-2 without the ER targeting signal peptide. PCR 
amplification yielded the expected band of approximately 714 bp. Restriction enzyme 
digests were carried out on PCV-2 cp with BspHI and XhoI and pCBP-2 with NcoI and 
XhoI. The PCV-2 cp plant codon-optimised gene was ligated into the pCBP-2 vector 
without a signal peptide to yield the pCBP-PCV 2 CP construct and was subsequently 
transformed into E. coli. 
The PCV-2 cp was successfully cloned into the pCBP-2 vector as colony PCR of E. 
coli transformants showed the presence of an expected band of 1011 bp (Figure 3.3 
A, green arrow) after amplification. Colony PCR of the empty vector control resulted 
in amplification of a fragment of approximately 423 bp (Figure 3.3 A, blue arrow), which 
was expected since the vector did not contain the gene of interest. Plasmid DNA was 
isolated from a positive E. coli clone and confirmed with DNA sequencing before 
transforming into A. tumefaciens GV3101::pMP90RK.  A total of 20 A. tumefaciens 
colonies were screened with colony PCR, all of which were shown to contain the gene 
of interest (Figure 3.3 B, green arrow). As expected, a band of approximately 423 bp 
was observed in an empty vector negative control (Figure 3.3 B, blue arrow). For the 
positive control (pEAQ-PCV-2-CP) in both experiments, a band of approximately 1000 






Figure 3.3 Colony PCR confirmation A) E. coli transformants. B) Agrobacterium 
transformants. The PCV-2 cp positive clones are indicated by the presence of PCR 
fragments of approximately 1011 bp (green arrow). The +ve control (pEAQ-PCV-2-
CP) yielded a band of approximately 1000 bp (green arrow). A band of approximately 
423 bp (blue arrow) was observed in the empty vector control and no bands were 
amplified in the no DNA template PCR negative control. M: represents the DNA 
molecular weight marker in base pairs. 
 
3.3.2 Large scale purification by ultracentrifugation 
Plants infiltrated with pCBP-PCV-2 CP in the presence of the pBIN-NSs silencing 
suppressor were harvested at 3 dpi, whereas pEAQ-PCV-2 CP-infiltrated plants were 
harvested at 4 dpi.  Biomass was partially purified according to the method described 
by Gunter et al. (2019), Chapter 2. The pellets obtained after ultracentrifugation were 
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resuspended in buffer and analysed on western blots and Coomassie-stained gels 
(Figure 3.4). From both the western blot (Figure 3.4 A) and the Coomassie-stained gel 
(Figure 3.4 B) it can be seen that the highest levels of PCV-2 CP (bands of 
approximately 27 kDa, black arrow) were obtained when expressed with pCBP-PCV-
2 CP compared to pEAQ-PCV-2 CP. As expected, no bands were observed in the 
empty vector negative control.  
 
Figure 3.4 Large scale expression and purification of PCV-2 plant-produced CP. 
A) Western blot analysis of PCV-2 CP probed using rabbit PCV-2 antisera (1:1000 
dilution) and anti-rabbit IgG alkaline phosphatase-conjugated secondary antibody 
(1:5000 dilution). B) Coomassie Blue stained SDS-PAGE gel of PCV-2 CP. M: Protein 
standard (kDa), -ve: Negative control (pCBP-2 empty vector). 
 
3.3.3 Caesium chloride (CsCl) purification 
To further purify PCV-2 VLPs, the pellet obtained after sucrose gradient centrifugation 
was subjected to CsCl density gradient centrifugation. Gradients were centrifuged until 
they reached isopycnic equilibrium. Isopycnic equilibrium is reached when the 
particles become concentrated in the gradient based on their densities. After 
centrifugation an opaque white band was observed in the CsCl gradient, indicated with 
a red arrow in Figure 3.5 A. The densities of the gradient fractions collected were 
determined using a refractometer. The refractometer analysis showed that the 
densities of the fractions varied from 1.658 g/cm3 to 1.285 g/cm3, fractions were further 
analysed by dot blot.  Based on dot blot analysis, the PCV-2 CP was concentrated in 
fractions 3-5 (Figure 3.5 C), corresponding to a CsCl density of 1.564 g/cm3-1.450 
g/cm3.  No protein was detected on the dot blots of the negative control samples 
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(Figure 3.5. D). Protein yields were too low for detection on western blots and 




Figure 3.5 PCV-2 CP CsCl density gradient purification. A and B) Photo and 
schematic representation of CsCl density gradient obtained after ultracentrifugation. 
C) Dot blot analysis of the pCBP-PCV-2-CP without a signal peptide and (D) the pCBP-
2 empty vector negative control. Dot blots were probed with rabbit PCV-2 antisera at 
a dilution of 1:1000, followed by probing with anti-rabbit IgG alkaline phosphatase-
conjugated secondary antibody (1:5000). 
 
3.3.4 TEM analysis of plant-made PCV-2 VLPs  
At first, after successful expression and purification (sucrose ultracentrifugation and 
CsCl density gradient) of PCV-2 CP in N. benthamiana using a construct that consist 
a signal peptide (Chapter 2, section 2.3.3), we evaluated if the CP has successfully 
assembled into VLPs. However, no VLPs were observed in expression time-trials (3, 
4, 6 dpi). A representative is shown (Figure 3.6 A). Our group has previously 
expressed VLPs using the pEAQ-HT vector and it was used as a positive control in 
the VLPs optimisation in this study. VLPs measuring between 12-20 nm were 
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observed for the positive control at 4 dpi and were consistent with the results obtained 
in Gunter et al. (2019) (Figure 3.6 B, yellow arrows). As expected, no VLPs were 
observed in the pCBP-2 empty vector negative control (Figure 3.6 C). 
 
 
Figure 3.6 TEM analysis of purified plant-produced PCV-2 CP: A) Construct pCBP-
PCV-2-CP-SP with an ER signal peptide, B) pEAQ-PCV-2-CP and C) The negative 
pCBP-2 empty vector. Samples were purified on sucrose discontinuous gradients and 
visualised at a magnification of 40 000 ×. Scale bars are 50 nm in size. Labels: yellow 
arrows: VLPs.   
 
Failure of the pCBP-2-expressed CP to assemble into VLPs was potentially due to the 
presence of the ER targeting signal peptide present on the pCBP-2 vector. It could be 
that the signal peptide sequence interferes with the normal cycle of production which 
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potentially stop VLP formation. Therefore, PCV-2 cp was cloned into pCBP-2 without 
the signal peptide.  
Expression time-trials were carried out with the construct lacking the signal peptide, 
pCBP-2-PCV-2-CP, protein was purified on sucrose gradients at 4, 5 and 6 dpi and 
analysed for VLPs.  Pellets were diluted 1:10, 1:20 and 1:40 in 1 x PBS, pH 7.4 and 
TEM analysis showed the presence of fully assembled VLPs ranging from 12-20 nm 
in diameter at 6 dpi (Figure 3.7 A-C, yellow arrows). Samples of the empty vector 
negative control were visualised at each dilution and no VLPs or similar structures 
were observed, a representative electron micrograph is shown in Figure 3.7 D.  
 
 
Figure 3.7 Electron micrographs of plant-produced PCV-2 VLPs (pCBP-PCV-2-
CP): VLPs were purified by discontinuous sucrose gradient centrifugation and 
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resuspended in 1x PBS, pH 7.4 before TEM analysis. Grids were observed at a 
magnification of 40 000 ×. The negative control (D, empty pCBP-2 vector) was also 
analysed, and a representative electron micrograph is shown. Scale bars are 50 nm 
in size. Labels: yellow arrows: VLPs.  
 
3.3.5 Optimisation of VLP purification  
3.3.5.1 Density gradient purification 
The recombinantly expressed PCV-2 CP was shown to successfully assemble into 
VLPs, however after plating the partially purified pellets on LB agar lacking antibiotics 
it was found that the samples were contaminated with bacteria.  Therefore, purification 
of these VLPs was optimised in order to remove bacterial contamination, this is of the 
utmost importance in order to achieve accurate results in diagnostics.  
In an attempt to obtain VLPs free of contamination, the resuspended pellet obtained 
after sucrose gradient centrifugation was filter sterilized through a 0.22 µm syringe 
filter. The sterile filtered protein was analysed on a western blot and Coomassie-
stained SDS-PAGE gel as well as with TEM. Unfortunately, no VLPs were recovered 
from the filter as no band was observed on either the western blot or Coomassie-
stained gel; furthermore, no VLPs were observed with TEM analysis (results not 
shown). Another approach was to freeze and thaw the VLPs at -20 °C for a duration 
of 1 hour for 5 cycles. Samples were collected after each freeze-thaw cycle and 
analysed. No VLPs were recovered after the 3rd freeze and thaw cycle (results not 
shown) and samples remained contaminated with bacteria.  
Since the pelleted VLPs could not be treated to remove bacterial contaminants, we 
investigated optimisation of the purification method as we hypothesised that bacteria 
present in the crude plant extract may have been pelleted with the VLPs during 
ultracentrifugation. Two methods of density ultracentrifugation were explored where 
VLPs were not pelleted during centrifugation.  
The first purification method involved extracting PCV-2 VLPs in 1x PBS, pH 7.4 and 
subsequent ultracentrifugation of the homogenate on discontinuous sucrose gradients 
for 18 hours at 20 000 × g at 4°C. Fractions of 1 ml were collected from the gradients 
and analysed on western blots (results not shown) and Coomassie-stained gels. PCV-
2 CP (approximately 27 kDa) was observed across almost all the fractions with the 
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highest concentration of CP observed in fractions 3-5 (Figure 3.8 A & B). The fractions 
were assessed for bacterial contamination and all fractions, except fraction 3, were 
free of contamination. Fractions 3–6 were analysed with TEM and showed the 
presence of fully assembled VLPs, an EM image of fraction 5 is shown as a 
representative (Figure 3.8 C, green arrows). Based on the Coomasie-stained gels, 
host cell proteins were co-purified together with the protein. This could explain the 
reason why protein aggregates were observed under EM analysis.  
 
Figure 3.8 Sucrose gradient purification. A and B) Coomassie blue stained gel of 
the sucrose fractions. A band of 27 kDa was observed across all fractions (F1-F12). 
C) EM analysis of fraction 5 as a representative for fraction 3-6. VLPs ranging between 
12-20 nm in size are indicated with the green arrow. Scale bars: 100 nm. M: Protein 
molecular ladder in kDa 
 
The second gradient purification method involved extracting PCV-2 VLPs in DB150 
buffer and centrifugation on discontinuous sucrose gradients (Section 2.2.5.1), 
followed by further purification on an Optiprep™ gradient. After sucrose gradient 
ultracentrifugation, the 30-50% sucrose fractions appeared brownish to green (blue 
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arrow), with a green band observed (purple arrow) at or just above the 50% sucrose 
fraction (Figure 3.9 A and B).  
 
Figure 3.9 Two-step gradient centrifugation for purification of plant-produced 
PCV-2 VLPs. Photo and schematic representations of; A and B) discontinuous 
sucrose gradient (20%, 30%, 40%, 50%, 60% and 68%); C and D) discontinuous 
OptiprepTM gradient (20%, 30%, 40% and 50%). Labels: Blue arrows - VLPs; purple 
arrows - native plant proteins. 
 
No pellet was observed after ultracentrifugation. Fractions (1 ml) of 20-68% sucrose 
were collected by bottom puncture and analysed on dot blots. Dot blot analysis of the 
18 fractions collected from the sucrose gradient showed the presence of CP in 
fractions 8-11 (Figure 3.10 A). No protein was detected on dot blots of the negative 
control empty vector (Figure 3.10 B). For contamination screening only the PCV-2 CP 
F1 and F4 had bacterial contamination, whereas F2, F3, F6, F9 and F16 of the 
negative control were shown to have contamination and was excluded from further 
purification.  
Fractions that were free of contamination (F8, F9, F10, F11, F12, F16, F17 and F18) 
were pooled and diluted in 1× PBS (pH 7.4) before loading onto discontinuous 
OptiprepTM gradients. After ultracentrifugation, a light green band was observed in the 
30%-50% OptiprepTM fractions (Figure 3.9 C and D, blue arrow), this is where 
assembled PCV-2 VLPs were expected. No pellet was observed after 
ultracentrifugation. A volume of 750 µl fractions were collected from the bottom of the 






Figure 3.10 Dot blot analysis of sucrose fractions second purification attempt 
for plant-made PCV-2 VLPs. A: Sucrose fractions for PCV-2 CP and B: negative 
control pCBP-2 empty vector. The blots were probed with PCV-2 rabbit antisera 
(1:1000 dilution) and anti-rabbit IgG alkaline phosphatase-conjugated secondary 
antibody (1:5000). 
 
After Optiprep™ purification the gradients were analysed on western blots.  Western 
blots showed the presence of a band of approximately 27 kDa in fractions 2-6 (Figure 
3.11 A, green arrow). The intense band observed just below the expected CP band in 
Fractions 3-5 could potentially be a cleaved product which can be explained by 
multiple proteases present in tobacco plants. No band was observed in the negative 
control empty vector samples (Figure 3.11 B). Fractions 2-5 collected from the 
OptiprepTM gradients were analysed with TEM and showed the presence of PCV-2 CP 
aggregates and very few VLPs (results not shown). Fractions 2 and 4 were 
contaminated while the rest of the fractions were free of contamination. These 
purification experiments were carried out twice and some fractions were free of 
contamination while others had contamination, rendering the method non-






Figure 3.11 Western blot analysis of Optiprep™ fractions second purification 
attempt for plant-made PCV-2 VLPs. A-B) Western blot (OptiprepTM) for PCV-2 CP 
and negative control pCBP-2 empty vector, respectively. Purified PCV-2 CP were 
probed with PCV-2 rabbit antisera (1:1000 dilution) and anti-rabbit IgG alkaline 
phosphatase-conjugated secondary antibody (1:5000). Labels: M: pre-stained protein 
standard (kDa); green arrow PCV-2 CP (approximately 27 kDa). 
 
3.3.5.2 Ion exchange chromatography purification (IEC) 
Since ultracentrifugation purification showed inconsistent results, purification of PCV 
VLPs using IEC was explored. After centrifugation and filtration, the crude extract was 
split in two: for one half the pH was dropped to pH 4; and for the other the pH was not 
adjusted and remained at pH 6.8 (which was the pH measured after extraction). After 
centrifugation, the supernatant was recovered, and the exact volume was measured. 
Both crude extracts were subjected to (NH4)2SO4 precipitation. Following (NH4)2SO4 
precipitation and subsequent IEC purification, western blot analysis of fractions eluted 
from the column showed that the pH 4 samples contained PCV-2 CP (approximately 
27 kDa) in the flow through and in the 1st wash. The bulk of the protein was detected 
in fractions 2, 3 and 4 eluted off the column (Figure 3.12 B). No bands were observed 
in the 30% (NH4)2SO4 sample where the pH of the crude was not adjusted (Figure 





Figure 3.12 Western blot analysis of IEC purified PCV-2 VLPs. A) The 30% 
(NH4)2SO4 (No pH adjustment). B) 80% (NH4)2SO4 pH 4. Purified PCV-2 CP were 
probed with PCV-2 rabbit antisera (1:1000 dilution) and anti-rabbit IgG alkaline 
phosphatase-conjugated secondary antibody (1:5000). Labels: FT: Flow-through; M: 
pre-stained protein standard (kDa); purple arrow PCV-2 CP (~ 27 kDa). 
 
Based on the western blot results, fractions 2, 3 and 4 were trapped on grids for EM 
analysis. PCV-2 VLPs ranging from 12-20 nm were observed in all these fractions 
(Figure 3.13). The highest concentration of VLPs was observed in fraction 2. Due to 
time constraints and COVID-19 global pandemic, I was unable to repeat this 
experiment or do a negative control. However, these results were promising and 



















Figure 3.13 Electron micrographs of IEC-purified plant-produced PCV-2 VLPs: 
Samples were purified by IEC before TEM analysis. The samples observed at the 










Table: 3.2 A summary of the purification methods investigated in this study 
Method used Contamination VLPs 
 







Sucrose gradient ultracentrifugation 
(pelleting) 
Extraction buffer: DB150, 
Ultracentrifugation speed and 
















Sucrose gradient ultracentrifugation 
without pelleting 
Extraction buffer:  1× PBS (pH 7.4) 
Ultracentrifugation speed and 














OptiprepTM via sucrose gradient 
ultracentrifugation 
Extraction buffer: DB150 











Method 4 IEC No Yes 
 
 
3.3.5.3 Production of PCV-2 VLPs in E. coli 
The aim of this section was to express the PCV-2 CP in E. coli for their trial use in the 
development of a lateral flow devices while the plant-made PCV-2 VLPs were being 
optimized. Eventually, E. coli – and plant-produced VLPs were assessed in the lateral 
flow development.  
E. coli expressed protein was partially purified using the BugBuster® purification 
method and the final pellet was washed six times with 1× PBS (pH 7.4) and the final 
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pellet resuspended in the same buffer. The resuspended final pellet obtained after 
partial purification of E. coli-produced PCV-2 CP was analysed on a Coomasie- 
stained SDS-PAGE gel. A band of approximately 27 kDa was observed in the 
pPROEX-HTc-PCV-2 construct, indicating the presence of the PCV-2 CP (Figure 3.14, 
green arrow). No band corresponding to the size of CP was observed in the pPROEX-
HTc empty vector which served as a negative control (Figure 3.14).  
 
Figure 3.14 Expression of E. coli-produced PCV-2 CP. Coomassie-stained SDS-
PAGE gel of pPROEX-HTc-PCV-2 and pPROEX-HTc empty vector. A band of 
approximately 27kDa was present in the pPROEX-HTc-PCV-2 as shown by a green 
arrow. No band was seen in the empty vector negative control. M: pre-stained protein 
standard (kDa).  
 
Following the Coomasie blue stain SDS-PAGE analysis, the protein was subjected to 
quantification and TEM analysis as described in section 2.2.4.  E. coli-produced PCV-
2 CP was quantified relative to known amounts of BSA (58 kDa) using gel 
densitometry. A BSA standard curve was generated, from which the unknown protein 
concentrations were calculated (Figure 3.15). The PCV-2 CP band was detected at 
the expected size of approximately 27 kDa (Figure 3.15 A). A second band of 54 kDa, 
double the size of the native PCV-2 CP, was also detected and quantified. This band 
could potentially be a CP dimer. A total CP yield of 0.191 mg/ml and 0.190 mg/ml were 
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obtained for the PCV-2 CP dimer and PCV-2 CP, respectively. The total CP yield was 
0.281 mg/ml. 
 
Figure 3.15 Gel densitometry analysis of PCV-2 CP. Quantification of E. coli 
expressed pPROEX-HTc-PCV-2 (A) assessed through densitometry evaluation of the 
appropriate bands, the blue arrow shows the PCV-2 CP band of approximately 27 kDa 
while the green arrow shows the CP dimer of approximately 54 kDa. Each BSA 
standard concentration is indicated above the lane (A). The absorbance is shown in 
the table for each standard and CP (B). C shows the BSA standard curve, the equation 





The E. coli-produced PCV-2 CP was subjected to TEM analysis to evaluate if the E. 
coli-produced protein was able to assemble into VLPs.  VLPs of a size range between 
12- 20 nm were observed in the pPROEX-HTc-PCV-2 CP (Figure 3.16 A) sample.  
These VLPs resembled the VLPs purified using IEC. No VLPs were observed in the 
pPROEX-HTc empty vector negative control (Figure 3.16 B). 
 
 
Figure 3.16 TEM analysis of purified E. coli-produced PCV-2 CP: A) pPROEX-
HTc-PCV-2 and B) pPROEX-HTc empty vector. Samples were purified using the 
BugBuster® purification protocol and visualised at a magnification of 40 000 ×. Scale 
bars are 50 nm in size. Labels: yellow arrows: VLPs.   
 
3.3.6 Lateral flow development 
This part of the study was conducted by Antrum Biotech (Pty) Ltd and the aim was to 
assess if E. coli- and plant made VLPs and the polyclonal antibodies raised in rabbits 
against PCV-2 CP (Gunter et al., 2019) could be used as antigen and antibodies in 
the development of the lateral flow assay. 
Initially, polyclonal antibodies were isolated from rabbit sera utilising two methods, 
protein A purification or ammonium sulphate precipitation. The ability of HRP 
conjugated antibodies to bind coated PCV-2 VLPs, using a direct ELISA, was 
investigated in order to determine whether the conjugation was a success. As 
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indicated by their affinity for E. coli and/or plant expressed PCV VLPs, both the protein 
A isolated and precipitated antibodies were successfully conjugated to HRP. Protein 
A isolated conjugated polyclonal antibody, however, outperformed precipitated 
conjugated polyclonal antibody because it showed similar affinity for PCV VLPs 
expressed by plant or E. coli at all conjugated antibody concentrations (results not 
shown). The purity of each of the antibodies was assessed on an SDS-PAGE gel and 
the presence of a heavy chain was observed in both antibodies. The light chain was 
not observed in the precipitated IgG (Figure 3.17). 
 
Figure 3.17 Purity of the antibodies. IgG protein A antibody showed the presence 
of a heavy chain (approximately 60 kDa) and a light chain (25 kDa). IgG precipitated 
antibody showed the presence of a heavy chain at approximately 80 kDa. No light 
chain was observed in the precipitated IgG antibody. 
 
The functionality of the antibodies was assessed by direct ELISA using both E. coli 
and plant made VLPs. Based on the ODs of the ELISAs Protein A isolated antibodies 
were found to be functionally superior (higher ODs) compared to precipitated antibody 
(Table 3.3). Both antibodies showed higher affinity for E. coli expressed VLPs when 








Table 3.3: The optical densities (ODs at 450nm) for each antibody interaction. 
Optical density readings, highlighting 
unconjugated antibody affinity for PCV-2 VLPs 
IgG protein A IgG precipitated 












2.391 2.575 0.513 0.489 
0 µg/ml 
(blank) 
0.24 0.236 0.081 0.081 
 
Serological based lateral flow assays involve coating nitrocellulose membranes with 
VLPs and detecting antibodies against the antigen (VLPs) in the sample.  The coating 
method was optimised by comparing different incubation temperatures (overnight at 
4°C, overnight at room temperature and 2 hours at 37°C) of antigen on the 
nitrocellulose membranes. It was found that incubation of the antigen overnight at 
room temperature or for 2 hours at 37°C resulted in optimal binding of the VLPs to the 
nitrocellulose membrane.  
In order to optimize the lateral flow, two alternative strategies were developed for 
detecting antibody; these were: double mix and triple mix. The procedures are outlined 
in methods Section 3.2.7. Both strategies showed positive outcomes with specific 
detection of antibody in buffer being observed. The antibody was diluted in buffer 
before applying to the test strip Initial limit of detection (antibody in buffer) was done 
in which the concentration of unconjugated precipitated antibody was serially diluted 
in buffer (to mimic the sample) to determine whether the serological lateral flow assay 
can detect clinically relevant concentrations of antibody in serum and thus, is fit-for-
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purpose. Specific antibody detection was observed at concentrations four-fold lower 
than the original concentration in both double and triple mix lateral flow assay set-ups.  
The final phase of the project involved determining the limit of detection and whether 
the test is fit-for-purpose in a sample matrix of interest. The lateral flow nitrocellulose 
membrane was coated with VLPs using the IsoFlow™ instrument in order to apply the 
VLPs to the nitrocellulose membrane in a homogenous line. These IsoFlow™ coated 
lateral flow strips were subsequently analysed for their ability to detect the anti-PCV-
2 antibodies in buffer. The lateral flow assays were analysed using both the double 
and the triple mix strategies as described in methods under Section 3.2.7. In addition, 
both the precipitated anti-PCV-2 antibodies and the protein A purified antibodies were 
used for these experiments. Results from these initial experiments on the lateral flow 
strips coated with the IsoFlow™ instrument indicated that using either the precipitated 
or protein A purified anti-PCV-2 antibodies in both a double and a triple mix, produced 
a positive signal on the test strips. However, using the triple mix strategy with the 
precipitated anti-PCV-2 antibody resulted in the most pronounced positive signal and 
therefore this combination was used to determine the initial limit of detection of the 
antibody in buffer.  
To determine the limit of detection of the antibody in buffer, the concentration of the 
unconjugated precipitated antibody was serially diluted (1 to 1:128) and applied to the 
lateral flow strips using the triple mix strategy. A positive signal was obtained down to 
a 1:16 dilution of the unconjugated precipitated antibody within 7 minutes and down to 





Figure 3.18: Triple mix: Sample (unconjugated precipitated IgG) diluted from 1:2 to 
1:128 pre-incubated with the secondary detection antibody and strep-HRP applied to 
the strips followed by chromogen application. Red arrow shows the test line while the 
green arrow shows the negative control line. 
 
Lastly, as a proof of concept that the nitrocellulose membrane can be coated with a 
negative control line and a test line simultaneously (on one test strip) and still result in 
a valid test, lateral flow strips were coated with the E. coli-expressed VLPs (test line) 
and a negative control line (buffer) using the IsoFlow™ instrument. Each test strip thus 
included a negative control and a test line. The unconjugated precipitated antibody 
was subsequently applied to the lateral flow strips in serum at the original 
concentration, 1:2, 1:4 and 1:8 dilutions using the triple mix strategy (Figure 3.19). The 
results indicated that the lateral flow strips coated with both a negative control line and 




Figure 3.19 Triple mix: Sample (unconjugated precipitated IgG in serum) diluted from 
1 to 1:8 pre-incubated with the secondary detection antibody and strep-HRP applied 
to the strips followed by chromogen application. Red arrow shows the test line and the 

















The CP of PCV-2 can self-assemble spontaneously into VLPs that are of significant 
biopharmaceutical use (Duan et al., 2019, Chae, 2012). The transient plant-based 
expression system is just one of the many systems for production of recombinant 
proteins and it has been demonstrated to be easily manageable and cost effective (Ma 
et al., 2003, Kopertekh and Schiemann, 2019).     
In this chapter, I focused on investigating if recombinantly expressed PCV-2 CP 
expressed with the novel pCBP-2 vector was able to assemble into VLPs. VLPs have 
the ability to serve as strong antigenic component for use in vaccine and diagnostic 
assay development (Frietze et al., 2016, Wang et al., 2020). VLPs are safe to use and 
it is possible to produce high-quality, reproducible antigen on a large scale compared 
to inactivated or live-attenuated antigens (Noad and Roy, 2003, Raghunandan, 2011).  
Initially the PCV-2 cp was cloned into pCBP-2 that had an LPH signal peptide to direct 
protein synthesis in the ER. Gunter et al. (2019) showed that best expression was 
obtained with pEAQ-HT, which targets protein expression to the cytoplasm; therefore 
my aim was to improve on his findings to increase expression levels of CP. Based on 
the intensity of bands observed on a Coomassie-stained gel (Figure 3.4), higher levels 
of CP was expressed with pCBP-2 compared to expression with pEAQ-HT.  These 
results showed that the novel pCBP-2 vector outperformed the pEAQ-HT vector for 
recombinant expression of PCV-2 CP. However, even though it was shown that 
expression with this vector resulted in higher accumulation of CP compared to 
expression with pEAQ-HT, no VLPs were observed after purification (Figure 3.6). The 
LPH signal peptide added extra amino acids to the N terminal of the CP which 
potentially interfered with VLP formation. Therefore, PCV-2 cp was cloned into pCBP-
2 without the LPH signal peptide, which resulted in protein expression being targeted 
to the cytoplasm.  The removal of this peptide sequence resulted in expression of CP 
as well as assembly into VLPs in the cytoplasm (Figure 3.7).  
Expression time-trials were carried out to assess when CP expressed with pCBP-2 
(without a signal peptide) would yield the most VLPs (results not shown). The pCBP-
2 yielded higher levels of CP than the pEAQ-HT vector. VLPs that were similar to 
native virions and VLPs produced with other recombinant expression systems ranging 
between 12-20 nm in size were observed at 6 dpi (Figure 3.7) (Nainys et al., 2014, 
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Masuda et al., 2018). Initially it appeared as though low amounts of VLPs were 
observed in the resuspended pellet after sucrose gradient purification. This was 
potentially because the resuspended pellet sample was concentrated and densely 
populated with proteins, or the presence of sucrose or co-purification of plant proteins 
made it difficult to observe isolated particles during TEM analysis. After diluting the 
samples many VLPs were observed in the 1:10 dilution and the amount of the VLPs 
observed decreased as the sample was further diluted. Furthermore, grid staining was 
optimised by reducing the staining time from 1 minute to 30 seconds to avoid 
overstaining.   
Purity is crucial when preparing VLPs for use as a diagnostic reagent (Bhat and Rao, 
2020). Even though high levels of recombinant proteins are necessary to achieve 
competitive yield, consideration must also be given to the effective recovery of proteins 
of purity. Partial purification of the VLPs used in this study involved the use of density 
gradient ultracentrifugation which is a regularly used method to purify VLPs from 
various expression systems (Gunter et al., 2019, Wu et al., 2012, Regnard et al., 2017, 
Rowell, 2019, Khayat et al., 2019). In the current study, plant-made CP was partially 
purified by concentrating the CP in a pellet which has passed through both a 45% and 
65% sucrose cushion. After ultracentrifugation, PCV-2 VLPs were observed with EM 
in the pelleted samples (Figure 3.7).   These results were similar to previous results 
reporter by (Gunter et al., 2019). Although this method has been often used to purify 
VLPs produced in various systems, we consistently observed that our samples were 
contaminated with bacteria.  It was possible that concentrating the CP in the pellet, 
resulted in co-precipitation of bacteria associated with the plants.  Therefore, we set 
about to optimise the purification strategy for obtaining higher purity and sterility of 
PCV-2 VLPs. 
At first attempts were made to remove bacterial contamination from already purified 
VLPs.  VLPs were filter sterilized through 0.22 µm syringe filters. Filtering is an easy 
and often used method to sterilise media and protein after purification (Nail and Akers, 
2012, Fishman and Berg, 2019). After filter-sterilizing the protein was lost on the filters 
(results not shown). This could have been because the filters had a high protein 




Freeze–thaw of protein causes strong fluctuations in temperature which can damage 
or destroy microbial cells present in the protein and disrupt cell aggregates (Zuanazzi 
et al., 2020, Papanicolas et al., 2019). This method was employed to reduce bacterial 
load in the samples but led to a significant loss of protein after the 3rd freeze-thaw 
cycle, indicating that the VLPs were not stable during extreme temperature 
fluctuations.  Moreover, all samples remained contaminated.  
Since the VLPs could not be sterilised after partial purification, different purification 
methods were explored in this study.  These methods included ultracentrifugation and 
IEC. For ultracentrifugation, parameters such as the centrifugation speed and time 
which affects sedimentation of the VLPs were adjusted to ensure that the VLPs 
remained in suspension in the gradient fractions, rather than collecting them in the 
pellet. The first attempt of ultracentrifugation at a lower speed without pelleting used 
in this study involved extraction in 1× PBS (pH 7.4), here, CP and VLPs were observed 
in all the fractions with the highest concentration of CP observed in fractions 3-5 
(Figure 3.8). The second ultracentrifugation approach involved extracting CP in DB150 
buffer and load it on the sucrose gradients before pooling the fractions for OptiprepTM 
gradient. Figure 3.11 shows that the fractions analysed after the Optiprep™ gradient 
ultracentrifugation had the CP present in fractions 2-6. Although, ultracentrifugation 
performed in this study was successful at isolating VLPs, bacterial contamination 
results showed to be inconsistent as some of the fractions were contaminated while 
others were not. The purification method established in this study had to be 
reproducible to be able to continuously produce VLPs of high quality and purity for 
diagnostic assays. With this method, VLP fractions that were contaminated had to be 
discarded, which is an unnecessary waste of protein rendering the purification method 
ineffective and expensive.  
As the results obtained with ultracentrifugation were variable and not reproducible, we 
investigated the use of IEC for purification of PCV-2 VLPs. This method has 
successfully been used by previous researchers for purification of PCV-2 VLPs.  We 
investigated the method reported by Masuda et al. (2018) for the purification of plant-
produced VLPs. In the present study we investigated two extraction buffers: 1x PBS 
(pH 7.4) and DB150 (pH 6.8), for extraction of proteins from biomass. The DB150 buffer 
contains arginine which stabilize the proteins (Shmueli et al., 2019), extraction of the 
CP in 1x PBS (pH 7.4)  also demonstrated promising results, making it suitable for 
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extraction of the PCV-2 CP. Since extraction in PBS was preferred for IEC purification, 
CP extracted in 1x PBS (pH 7.4) was clarified and successfully purified using IEC 
(Figure 3.12). The PCV-2 CP produced in N. benthamiana was found to have a high 
affinity to the anion exchange column, these results were similar to that of the study 
by Masuda et al. (2018) in which the  PCV-2 CP was produced in silkworm and purified 
using the same method. Interestingly, it was shown by  Zaveckas et al. (2015) , that 
yeast-produced PCV-2 CP had high affinity to the cation exchange columns. Adjusting 
the pH of the crude extract from 6.8 to 4 prior to (NH4)2SO4  precipitation, significantly 
reduced the presence of host cell proteins in the sample and aided with greater 
recovery of  PCV-2 CP (Menzel et al., 2016, Martinez et al., 2019, Wu et al., 2014). It 
was shown previously that lowering the pH results in precipitation of host cell proteins, 
which results in the removal of the majority of host cell proteins from crude plant 
extracts and helps with the recovery of highly pure target protein (Martinez et al., 
2019); which is why this method was trialled in this study. EM analysis was carried out 
on fractions eluted off the IEC column and VLPs were observed in fractions 2,3 and 4 
which corresponds to 0.3 M, 0.45 M and 0.6 M NaCl respectively. More VLPs were 
observed in the 0.3 M NaCl eluted fraction and decreased as the concentration of NaCl 
increased (Figure 3.13). None of the fractions analysed after IEC purification showed 
the presence of bacterial contamination indicating that we were able to develop a 
method for the purification of PCV-2 VLPs.  
PCV-2 VLPs were made in E. coli and tested for their use in lateral flow devices while 
the optimization of VLP production in plants was underway. The PCV-2 CP was 
successfully expressed in E. coli, and assembled into VLPs ranging between 12-20 
nm, similar to those produced by (Marcekova et al., 2009). PCV VLPs which mimic the 
structure and size of native virions are easily produced in E. coli and can be detected 
by PCV-2 specific antibodies (Zhang et al., 2016). The E. coli-based pPROEX-HT 
expression method offers easy cloning and can efficiently express recombinant 
proteins (Polayes and Hughes Jr, 1994). The partially purified E. coli- produced VLPs 
were quantified for use in the development of a lateral flow assay and the yield was 
0.281 mg/ml (Figure 3.15). The expected band of 27 kDa for CP was observed on the 
Coomassie blue-stained gel, together with a CP dimer which is double the size of the 
native CP at approximately 54 kDa (Figure 3.14). Wu et al. (2016) reported the same 
observation for recombinant PCV-2 CP expressed in E. coli.  
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The rabbit-derived polyclonal antibodies that target PCV-2 VLPs were successfully 
isolated from the serum and were functional in both unconjugated and conjugated 
(HRP) form. Modification of the polyclonal antibody may occur during precipitation 
(lack of a light chain in SDS-PAGE image, figure 3.17), which impacts PCV-2 VLP 
affinity. This has been noted in functionality, modification and lateral flow experiments 
as protein A isolated IgG outperformed precipitated IgG. The lateral flow assay results 
showed that the serological lateral flow assay set-up can successfully detect the anti-
PCV-2 precipitated antibody in buffer (mimic antibody in serum sample), using 
nitrocellulose coated with E. coli expressed VLPs. Additionally, the results in this part 
of study show that the initial limit of detection was determined to be 1:16 of the original 
unconjugated precipitated anti-PCV-2 antibody concentration, indicating the potential 
of the lateral flow assays to detect the anti-PCV-2 antibodies in serum samples. The 
lateral flow assays are thus fit-for-purpose, suggesting their use in diagnosing PCV-2 
in swine herds. Once the diagnostic kit is ready for use, blood samples will be taken 
from swine for testing.  
In conclusion, fully assembled PCV-2 VLPs were successfully produced in N. 
benthamiana using the novel pCBP-2 plant expression vector. A simple and highly 
scalable IEC purification method was established to obtain pure VLPs for potential use 
as an antigen in diagnostics and vaccines. This method can easily be scaled up 
compared to ultracentrifugation. PCV-2 VLPs were used to develop a lateral flow. 
Recombinant expression of the CP in plants for use in diagnostic assays has not yet 
been reported on thus far, therefore the expression of this immunogenic protein in 












4 Chapter 4: General conclusions and future work 
 
The aim of this study was to assess expression of PCV-2 CP with the novel pCBP-2 
plant expression vector and optimising a purification method that would allow for 
recovery of CP of high purity.  The overall objective was to produce PCV-2 CP of high 
purity and yields using a reliable expression system that is easily scalable and would 
permit a fast response in terms of diagnosis and identification of the cause of the 
disease in the case of PCV-2 pandemic. Development of cheaper diagnostics can be 
useful in disease surveillance in the swine industry as tests can be carried out 
regularly. Since it has been reported that PCV-2 continuously undergoes genetic shifts 
(Burbelo et al., 2019, Franzo et al., 2020), this study is relevant to combat a wide range 
of PCVAD caused by emerging PCV-2 strains by producing a cheaper diagnostic 
reagent which may be useful in developing affordable diagnostics. With the new 
discovery of PCV-3 which was first identified in the United States thorough a 
metagenomics approach and is associated with various clinical syndromes, including 
gastrointestinal, reproductive, respiratory and neurological disorders in swine (Saporiti 
et al., 2020a, Palinski et al., 2017b, Phan et al., 2016a), there is a need for ongoing 
research which may provide a platform for studies aimed at developing diagnostic 
tools or vaccines against this newly emerged genotype of PCV. It was proved that 
plant expression platform can be used to rapidly produce highly immunogenic PCV-2 
VLPs (Gunter et al., 2019). The finding of the study by Gunter et al. (2019) has led to 
this study with a focus on exploring the transient expression system, utilizing N. 
benthamiana to improve and produce PCV-2 VLPs with a better yields. In addition, 
various methods for improving purification of PCV-2 VLPs were investigated with the 
aim to establish a reliable purification method which allows recovery of VLPs that are 
of high purity and free of contamination.  
The pEAQ-HT vector which was previously the best vector for expression was directly 
compared to the novel pCBP-2 vector. Despite the fact that pCBP-2 vector had the 
best yield of protein, at first no VLPs were obtained when the vector had a signal 
peptide which led to further assessment of VLP formation using the same vector 
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lacking a signal peptide. Eventually VLPs were produced and the vector still 
outperformed the pEAQ-HT vector in terms of expression yields. This study is the first 
to report that the pCBP-2 expression vector can be used to achieve higher yields of 
PCV-2 CP compared to the previously studied pEAQ-HT expression vector. Based on 
gel densitometry analysis, PCV-2 yields (chapter 2) obtained using the pCBP-2 vector 
was approximately two-fold higher than that obtained with the pEAQ-HT vector. This 
does not include the observed CP dimer seen on the SDS-PAGE gel which could 
possibly increase the total protein yield. I further showed that co-expression with an 
RNA silencing expressor significantly enhance expression which enables achieving 
higher yield of protein.  
Moreover, I have shown that IEC purification method can be a potentially reliable, 
highly scalable and promising method of achieving pure VLPs. In order for plants to 
be a powerful system for the production of recombinant proteins, higher protein yields 
must be achieved, therefore continuous optimisation is crucial. As mentioned earlier, 
the most hindering factor of this project was time due to Covid-19 global pandemic 
hence troubleshooting could not be performed to a great extent. This would enable 
investigations of whether this method compromises the yield of the protein or not 
compared to sucrose purified protein. In addition, this experiment would require to be 
repeated with a negative control empty vector to validate the method. Nevertheless, 
IEC was a proof of concept which is promising as VLPs that were similar to those 
obtained in other studies were observed as discussed in section 3.4 of the previous 
chapter. 
The overall aim of this project was to express protein which could potentially be used 
as a reagent in diagnostic tests such as ELISA and lateral flow assays. In this study, 
plant-made CP and E. coli-made VLPs were expressed and used in the development 
of lateral flow assays using PCV-2 rabbit antisera. This is because it was difficult to 
get plant- made VLPs at first and by the time the lateral flow work was ongoing, I was 
still optimizing VLPs production in plants. For this reason, after I successfully produced 
plant- made VLPs, the lateral flow work was already about to be completed. Even 
though, the idea was to test the functionality of these CP and VLPs using swine sera 
obtained from various sources using these tests, due to time constraints that did not 
happen and would have to be done in future and the limit of detection would be 
determined. The VLPs/CP were used as a coating reagent in the lateral flow 
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development and their functionality was assessed. Although all VLPs/CP showed 
satisfactory functionality, the E. coli expressed VLPs had higher affinity to both 
antibodies (IgG protein A and IgG precipitated) compared to plant expressed CP.  
This, however, does not necessarily means that the E. coli-made proteins are more 
potent than plant-made proteins as this could be explained by the fact that the 
antibodies were made in rabbits using the E.coli produced VLPs. Therefore, the 
epitope presentation on the E. coli produced VLPs might be different than that of the 
plant-produced CP, thus conformation of epitopes. Therefore, further optimization 
needs to be done to get a better understanding on this finding.  
Since a lateral flow device is a rapid and straightforward testing method which allows 
faster decision making and requires no expertise to interpret the results it is of 
paramount importance that plant-made VLPs’ functionality is assessed in the lateral 
flow in comparison to the E. coli-made.  Since proof of concept was shown for the 
lateral flow devices using E.coli VLPs and that the fundamental groundwork has been 
laid out, it would be beneficial to test pure, high quality plant-made VLPs produced in 
this study on diagnostic assays. Furthermore, the sensitivity and specificity of the 
immunoassays need to be analysed. Also, since the test lines of the lateral flow strips 
were not easily visible, future considerations would include refinement of the lateral 
flow assay to obtain clearer and more easily visible test lines on the lateral flow strips. 
Nonetheless this work successfully demonstrated that the PCV-2 VLPs are fit for use 
in the development of the lateral flow device for diagnostics purposes. 
Even though, the idea was to test the functionality of these CP and VLPs using swine 
sera obtained from various sources using these tests, due to time constraints (global 
pandemic) that did not happen and would have to be done in future and the limit of 
detection would be determined. In this study, all the necessary clearance such as 
section 20 and animal ethics was obtained for this part of the project which would 
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